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Abstract 
Duchenne muscular dystrophy (DMD) is a devastating neuromuscular disorder that affects 
approximately 1 in 5000 males. Vascular-targeted therapy has been proposed as a 
treatment for DMD to reduce ischemia and enhance endogenous repair. Additionally, a 
more vascularized environment may enhance regenerative approaches currently under 
investigation. Vascular endothelial growth factor (VEGF) and angiopoietin-1 (ANG1) are 
two of the most studied pro-angiogenic factors for this approach.  To date, little is known 
regarding the effect of these pro-angiogenic factors on muscle function and whether they 
may exacerbate fibrosis in a relevant murine model of DMD.  The first aim of this thesis 
was to determine the murine model that is best suited for assessing vascular therapy. We 
demonstrate the dystrophin null, utrophin heterozygous mouse (mdx/utrn+/-) develops 
more collagen deposition at an earlier age than the commonly used mdx mouse and is 
therefore a superior choice for assessing therapeutic effects on fibrosis. Next, we 
investigated the effect of exogenous VEGF treatment on fibroblasts derived from severely 
affected diaphragm and mildly affected gastrocnemius muscles of mdx/utrn+/- mice. 
VEGF treatment induced differentiation into myofibroblasts in both cell types, suggesting 
induction of a fibrotic response. The final aim of the thesis was to assess the effect of 
VEGF alone or in combination with ANG1 on functional perfusion as assessed non-
invasively using dynamic contrast-enhanced computed tomography. A combination of 
VEGF and ANG1, but not VEGF alone, slowed progression of ischemia in the mdx/utrn+/- 
hind limb. Increased vessel maturation, as assessed histologically, validated the imaging 
findings. The combination treatment also decreased fibrosis and leukocyte infiltration, 
consistent with decreased vascular permeability following ANG1 treatment. Overall, the 
research in this thesis highlights the drawbacks to use of VEGF as a treatment for ischemia 
associated with DMD and reveals considerations for future use of vascular therapy in 
murine models of the disease.  
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Project Proposal Summary 
BACKGROUND: The most commonly diagnosed fatal childhood disorder is Duchenne 
muscular dystrophy (DMD), a neuromuscular disease that is invariably fatal by the age of 
30. Regenerative therapy research has been ongoing for decades with little or no 
significant efficacy reported in pre-clinical trials. A major contributor to this inefficacy is 
the ischemia, inflammation, and fibrosis that progressively dominate the degenerating 
muscle tissue, creating a hostile environment for cell transplantation. Studies have 
proposed the use of angiogenic factors to alleviate the ischemia inherent to DMD 
pathology, creating a more optimal environment for regeneration. Vascular endothelial 
growth factor (VEGF) is a known potent inducer of angiogenesis and is of particular 
interest in the field given that preliminary. Recent studies have also proposed a 
combinatorial approach, using VEGF to induce angiogenesis and angiopoietin-1 (ANG1) 
to mature vessels, since VEGF alone is known to produce leaky vasculature. No studies to 
date have investigated whether these factors, either alone or in combination, affect 
perfusion longitudinally in a relevant animal model of DMD. There is also very little 
known regarding the effect, if any, these angiogenic factors may have on inflammation and 
fibrosis. Finally, much of what is currently known about vascular therapies is derived from 
invasive muscle biopsies that may contribute to disease progression and are limited in that 
they provide a small perspective of a very heterogeneous disease.  
HYPOTHESES: A combination of VEGF and ANG1, but not VEGF alone, will reduce 
disease progression in a murine model of muscular dystrophy and this effect can be 
measured non-invasively using dynamic contrast-enhanced computed tomography. 
SPECIFIC AIMS: 
i) Investigate histopathological features in the mdx, mdx/utrn+/- and dko mice to 
determine the suitability of each as a model of Duchene muscular dystrophy. 
Hallmark features that will be assessed include percentage of centrally 
nucleated myofibers and extent of fibrosis as indicated by Masson’s Trichrome 
staining.  
 vii 
 
ii) Determine whether VEGF elicits a pro-fibrotic response in fibroblasts derived 
from a murine model of DMD. Fibroblasts isolated from gastrocnemius and 
diaphragm muscles of 10 week-old mice will be treated with VEGF164. qPCR 
will be employed to measure changes in mRNA levels of fibrotic genes 
including Col1A, Ccn2/Ctgf, Acta2 and Fn1. 
iii) Assess the ability of VEGF alone or in combination with ANG1 to enhance the 
microenvironment in dystrophic murine skeletal muscle. Ex vivo analyses 
including immunohistochemistry and western blot will be used to measure 
changes in expression of: alpha smooth muscle actin (marker of mature blood 
vessels), CD45 (leukocyte marker), and collagen (fibrotic marker).  
iv) Use dynamic contrast-enhanced computed tomography (DCE-CT) to determine 
if ex vivo changes in angiogenic, inflammatory, and fibrotic markers observed 
in aim 3 correlate with functional changes in skeletal muscle perfusion.  
SIGNIFICANCE: Addressing the hostile regenerative environment in dystrophic muscle 
may address the lack of efficacy observed with current therapeutic approaches in DMD 
patients. The proposed research will further investigate the role of vascular-targeted 
therapy in vivo in a relevant animal model that more accurately reflects the 
pathophysiology of DMD in patients. The majority of current research utilizes histological 
and post-mortem means of assessing the effect of VEGF treatment, impeding accurate 
interpretation of the effect of treatment on muscle function. The proposed research is novel 
in that it will correlate CT findings with traditional histological analyses following 
treatment with pro-angiogenic agents to better elucidate the potential for its use in the 
clinical arena. 
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1
 A portion of this chapter includes content reproduced from: 
Gutpell K, Hoffman L. Non-invasive assessment of skeletal muscle pathology and treatment for Duchenne 
muscular dystrophy. OA Musculoskeletal Medicine 2013;1(4):33. 
 
2 
 
1 Introduction 
1.1 Chapter Summary 
Duchenne muscular dystrophy (DMD) is the most severe form of muscular dystrophy. It 
is also the most fatal genetic disorder diagnosed in children (Emery 2002). DMD is 
caused by a mutation, or mutations, in the gene encoding dystrophin, a large cytoskeletal 
protein that confers membrane integrity in muscle cells. Since dystrophin was discovered 
in 1987, many research groups have attempted to restore its expression in patients and 
animal models of the disease. Although promising results have surfaced in recent years, 
100% dystrophin expression has not yet been achieved, and thus muscle degeneration and 
accompanying fibrosis still occurs. As such, it is well accepted that any real cure to DMD 
will involve a multifaceted approach including methods to both restore dystrophin and 
alleviate the hostile muscular environment already present at the time of diagnosis.  
This chapter provides background on the underlying pathophysiology of DMD, 
therapeutic approaches under investigation to treat the disease, and some of the main 
limitations to current research. Important considerations in conducting DMD research are 
also discussed, including animal models of the disease and techniques for assessing 
functional efficacy of therapies. The aim of this chapter is to provide the overarching 
rationale for the research presented in this thesis.  
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1.2 Duchenne muscular dystrophy 
1.2.1 Living with DMD 
A DMD diagnosis is typically given within the first three to five years of life. The most 
common sign observed by parents is the onset of the “Gower’s maneuver,” whereby a 
child cannot use his leg muscles alone to stand up. Instead, he must use his arms to 
“walk” up his legs to reach a standing position. The first step in diagnosing DMD is 
testing levels of creatine kinase (CK), a metabolite of muscle breakdown (Van Ruetin et 
al. 2014). If CK levels are elevated, physicians will often order genetic testing on blood 
samples to determine if a mutation in the dystrophin gene is present. In some, but not all 
cases, a biopsy will be ordered to confirm a lack of dystrophin protein in the patient’s 
skeletal muscle.  
Once a diagnosis occurs, the life path that each child takes is unique, with some 
responding positively to treatments and living well into their thirties, and others 
succumbing to the disease by their late teenage years. Due to vast improvements in 
healthcare - particularly in the fields of cardiology and pulmonology - the former case is 
becoming increasingly common, with some DMD patients going to college, attaining a 
career and, in some cases, having children (Eagle et al. 2002). Nevertheless, DMD 
patients are limited to wheelchair mobility by approximately age 12 and the care they 
receive is purely palliative, with no current treatments offering an actual cure to date 
(Landfeldt et al. 2015). Eventually, patients succumb to the disease, typically due to 
respiratory complications (Cruz Guzmán et al. 2012, Wei et al. 2016).  
 
1.2.2 Murine models of DMD 
The most widely studied murine model of DMD is the mdx mouse, a dystrophin-null 
mouse that genotypically mimics the human form of the disease (Sicinski et al. 1989; 
Partridge et al. 2013). While this model exhibits classic histological features of muscle 
pathology such as centrally nucleated myofibers and inflammatory infiltrate, it is 
generally healthy until 10 months of age and nearly indistinguishable from a wild-type 
mouse (Stedman et al. 1991, Desguerre et al. 2012). Perhaps most importantly, the 
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disease does not manifest in the same manner as it does in patients, with very little 
skeletal muscle fibrosis observable at any point in the progression of the disease. The 
mdx diaphragm does develop increased fibrotic marker expression, but the extent of 
fibrosis is non-life threatening. Fibrosis and muscle degeneration of the diaphragm 
muscle is a major cause of death in DMD patients and is therefore an important feature in 
an accurate animal model. Further, fibrosis is nearly absent in the hind limb skeletal 
muscles, even at an advanced age. Considering that a large portion of tissue regeneration 
research in this field injects into this area, the lack of fibrosis in the mdx mouse may 
present a potential source of misinterpreted results.  A double knockout mouse lacking 
dystrophin and its analogue, utrophin (utrn), more closely phenocopies DMD (Grady et 
al. 1997). This double knockout mouse (dko) develops observable muscular dystrophy by 
4 weeks of age that rapidly progresses until death, which is typically around 16-22 weeks 
of age. Importantly, the dko mouse also develops fibrosis, which is a major contributor to 
the severity of DMD in patients (Isaac et al. 2013). Although this double knockout model 
is preferred over the mildly affected mdx mouse, it is difficult to keep this mouse alive 
through the course of a longitudinal study. Additionally, in our laboratory, we observe 
that disease severity ranges in this dko mouse, with some animals gaining very little 
weight, only up to 10g, and barely surviving to 8 weeks of age. On the other hand, we 
have a number of dko mice that grow up to 20-25g and survive with minimal intervention 
up to 20 weeks of age. This disparity we observe in our dko mice introduces a great deal 
of variability in our studies and makes interpretation of results difficult. Regardless, any 
therapy should exhibit efficacy in the dko mouse if it holds any real promise of affecting 
patients. Given these considerable issues with the mdx and dko models, the heterozygous 
mouse (mdx/utrn+/-) has received attention in recent years for its potential to act as an 
intermediate model, but the research findings to validate this model as superior to the 
mdx mouse are still lacking.  
 
1.2.3 DMD pathophysiology  
DMD is caused by an absence of dystrophin, due to one or more mutations in the gene 
that encodes the protein (Emery et al. 2002). Since the dystrophin gene is located on the 
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X Chromosome, a mutation almost exclusively affects males, with female carriers of the 
mutation rarely exhibiting a phenotype typical of DMD (Hoffman et al. 1987, Song et al. 
2011). In very rare cases, females may carry mutations on both X Chromosomes and 
therefore exhibit the full phenotype observed in male patients. The gene that encodes 
dystrophin is composed of 79 exons. One or more of these exons can be mutated, with 
exons 45-55 accounting for the most common sites of mutation (Blake et al. 2002). 
Although DMD is an inherited genetic disorder, the mutation may also arise 
spontaneously, accounting for 30-40% of DMD cases. Typically, these mutations result 
in a truncated protein due to the premature addition of a stop codon. In some cases, this 
truncation produces a protein that has reduced, but not completely absent, function (Laing 
et al. 2011). In these cases the disease phenotype is less severe and the patient would be 
diagnosed with Becker’s muscular dystrophy (Hoffman et al. 1989, Hoogerwaard et al. 
1999). When the mutation results in a truncated, non-functional protein, or no protein at 
all, patients are severely affected by the disease and are diagnosed with Duchenne’s 
muscular dystrophy. 
 
Dystrophin is a 427 kDa cytoplasmic protein. It is expressed in a variety of cell types, 
including, but not limited to, cardiac, skeletal, and smooth muscle cells. Dystrophin acts 
to link cytoskeletal actin filaments, the contractile units of myofibers, to extracellular 
matrix proteins, such as laminin (Figure 1.1). Dystrophin is a component of the 
dystroglycan complex, along with sarcoglycan and dystroglycan transmembrane proteins. 
This link provides a scaffold against which cells may contract and confers overall 
membrane integrity to myofibers (Rybakova et al. 2000). Disruption of this connection 
through loss of dystrophin leads to an increased susceptibility to injury due to mechanical 
stress. This lack of sarcolemma (muscle cell membrane) integrity leads to an increase in 
intracellular free calcium, which has been directly linked to an increase in proteolysis, 
leading to eventual cell death (Hopf et al. 1996). Rapid inflammation responds to this 
muscle necrosis. The infiltrating inflammatory cells are not only responsible for clearing 
away the necrotic muscle cells, but they are a major source of pro-fibrotic signalling 
molecules. Of particular importance is transforming growth factor beta (TGFβ), 
expressed by macrophages and other inflammatory cells, which act on resident fibroblasts 
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to induce differentiation into myofibroblasts. Myofibroblasts are largely responsible for 
laying down the collagen matrix that contributes to tissue rigidity and fibrosis (Desguerre 
et al. 2009, Klinger et al. 2012). This cascade of events continues throughout the life of 
the patient, with fibrotic and adipose tissue progressively dominating what was once 
functional skeletal muscle (Figure 1.2).  
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Figure 1.1: Dystrophin is an integral part of a protein complex that links the 
cytoskeletal elements in muscle cells to the extracellular matrix.  
As part of the dystrophin glycoprotein complex, dystrophin confers overall membrane 
strength to myofibers. The N-terminal domain of dystrophin interacts with actin and the 
C-terminal domain interacts with the dystrophin-associated glycoprotein (DAG) 
complex, composed of sarcoglycans and dystroglycans. The DAG complex binds to 
extracellular proteins in the basal lamina, such as laminin. Additionally, neuronal nitric 
oxide synthase (nNOS) interacts with dystrophin between exons 42-45 at the 
sarcolemma, an interaction that confers enzymatic activity to the protein.  
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Figure 1.2: An X-linked mutation in the dystrophin gene leads to rapid decline in 
muscle function.  
A two-hit hypothesis is used to describe the pathways by which DMD progresses. 
Reduced sarcolemma integrity results in an increased susceptibility to contraction-
induced cellular damage. Damaged muscle tissue is continually replaced by fibrotic and 
adipose tissue. At the same time, reduced nNOS activity leads to impaired vasodilation, 
resulting in ischemia. Many therapeutic approaches aim to restore dystrophin in muscle 
tissue. 
Absence'of'dystrophin'
Decline'in'muscle'
func5on'
9 
 
1.2.4 Muscle ischemia due to loss of dystrophin 
Accompanying muscle degeneration is a progression of muscle ischemia in both DMD 
patients and animal models of the disease (Sander et al. 2000). While the primary 
function of dystrophin is to anchor the sarcolemma to the extracellular matrix for 
structural stability, its presence is also important for a number of other functions in 
skeletal and smooth muscle cells. Dystrophin functions as a signal transducer for the 
catalytic activity of neuronal nitric oxide synthase (nNOS). Through a physical 
interaction with dystrophin, nNOS catalyzes the production of nitric oxide (NO) in 
skeletal muscle (van den Bergen et al. 2015, Shiao et al. 2004). NO plays a key role in a 
variety of skeletal muscle cell functions including force production, regulation of blood 
flow, and glucose metabolism (Sander et al. 2000). Thus, with reduced nNOS activity, 
many normal functions of muscle may be impaired.  Additionally, loss of dystrophin in 
smooth muscle cells leads to an inability to produce vasodilation when an increased 
metabolic load is placed on skeletal muscle tissue (Ito et al. 2006). As a result, there is an 
unopposed sympathetic vasoconstriction leading to decreased muscle perfusion in 
patients with DMD. Work by others has shown there is an increase in vasoconstriction in 
DMD patients as indicated by a 16% decrease in blood flow compared to healthy forearm 
muscle. Blood oxygenation is also 7% lower in DMD muscle (Sander et al. 2000). 
Muscle biopsies from these patients confirm this difference in blood flow corresponds to 
decreased nNOS protein levels in DMD patients.  Immunohistological analysis of nNOS 
shows almost no expression of the protein at the sarcolemma. The importance of 
dystrophin in regulating nNOS activity is further demonstrated in transgenic mdx mice 
expressing smooth muscle-specific dystrophin whereby they exhibit improved 
vasoregulation compared to normal mdx mice. While vasodilation is not increased to that 
of a wild type mouse in the transgenic mice, blood flow is significantly increased 
compared to mdx mice lacking dystrophin in smooth muscle cells (Kobayashi et al. 
2008). Overall, the deleterious effect of nNOS inactivity in DMD patients highlights a 
severe need for improved vasorelaxation in DMD patients.  
 
In addition to reduced nNOS activity in dystrophic muscle cells, there is increasing 
evidence to suggest that the vascular network in dystrophic tissue is also compromised. A 
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decrease in vascular density has been demonstrated in the mdx mouse (Loufrani et al. 
2004 & Asai et al. 2007). Microfilm perfusion has been used to visualize the total 
vasculature in the tibialis anterior muscle of the mdx mouse to demonstrate a reduced 
vascular network in the mdx mouse compared to healthy controls (Matsakas et al. 2013). 
Standard immunohistochemical techniques also indicate reduced arteriole density in mdx 
mice. It has not been reported whether a decrease in vascular density exists in DMD 
patients, but it is well known that fibrotic and fatty deposits progressively dominate 
muscle tissue in DMD patients. The dense, fibrotic connective tissue that displaces 
muscle is not well vascularized and therefore may impede blood delivery to the tissue. 
Without proper blood flow, muscle regeneration, by endogenous repair mechanisms or 
exogenous dystrophin delivery, may not occur. Enhancing the vascular environment by 
increased vascular density may confer some of the function that is aberrant due to a lack 
of dystrophin. 
 
Dystrophin absence in endothelial cells (ECs) has also been linked to impaired 
angiogenesis in mdx mice (Palladino et al. 2013). Although dystrophin was classically 
considered to be a muscle-specific protein, this study demonstrates the importance of its 
expression in ECs as well. As with muscle cells, the loss of nNOS activity at the EC 
membrane leads to a cGMP deficiency that affects not only blood blow, as previously 
discussed, but also impairs the ability of ECs to migrate, proliferate, and form tubules in 
in vitro culture assays. Interestingly, a low dose of aspirin aided in EC production of NO 
and cGMP, leading to an increase in microvascular density post-treatment. These 
findings shed a new light on the use of pro-angiogenic growth factors for enhancing the 
microvasculature in mdx mice and DMD patients. Prior to this study, little attention has 
been given to the possibility that, regardless of growth factor treatment, there may be an 
inherent impairment in EC ability to form new vessels in muscular dystrophy.  Thus, the 
results of this study may help explain differences in angiogenesis following treatment in 
dystrophic compared to healthy muscle.  
 
There is evidence of decreased vasodilation, vascular density, and angiogenic capability 
in dystrophin-related myopathy. Taken together, studies relating to ischemia in DMD 
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highlight the need to not only address ways to regenerate muscle cells, but also address 
the vascular problems inherent in this pathology. Without proper vasculature, 
regenerative techniques to restore dystrophin may be rendered futile.  
 
1.3 Strategies to restore dystrophin 
Given the importance of dystrophin in nNOS activity and conferring sarcolemma 
integrity, a number of groups are attempting to restore dystrophin expression in animal 
models of DMD. Some of the most promising approaches to restoring dystrophin include 
exon skipping, genome editing using the Crispr/Cas9 system, and stem cell therapy.  
 
1.3.1 Exon skipping 
When a genetic mutation disrupts the reading frame of nucleotide triplets, or codons, the 
result may be a truncated protein. This is the case in DMD whereby a mutation in one or 
more exons leads to a premature stop codon, resulting in a truncated, non-functional form 
of the dystrophin protein. In most cases, this truncated version of the protein is not even 
detectable as dystrophin. Fortunately, cells have an inherent ability to excise, or “splice”, 
introns, which are portions of a pre-mRNA strand that do not contribute to the amino acid 
sequence of a peptide. Researchers have exploited this innate machinery in cells to splice 
out the mutated exons in the dystrophin gene (Hoffman et al. 2014). The result is an 
imperfect, but largely functional, dystrophin protein. Eteplirsen, developed by Sarepta 
Therapeutics, has been used in Phase III clinical trials to treat patients with a mutation in 
exon 51, one of the more commonly mutated sites in DMD.  The United States Food and 
Drug Administration is reviewing Sarepta’s New Drug Application for Eteplirsen in 
February 2016. Although only 13% of DMD patients may be amenable to exon 51 
skipping, this technology could significantly improve quality of life for that patient 
population (Mendell et al. 2016). It is important to note, though, the dystrophin expressed 
in these cases often lacks its full function and only improves the disease phenotype to a 
less severe form, one similar to that observed in Becker’s muscular dystrophy. 
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1.3.2 Genome editing 
In contrast to exon skipping, whereby the mutation is left intact and a downstream target 
(RNA) is manipulated, genome editing involves correcting the mutation that is embedded 
in the genetic code. A powerful new genome editing tool known as clustered regularly 
interspaced short palindromic repeat/Cas9 (CRISPR/Cas9) has emerged as one of the 
most promising tools of the 21st century. This system involves the use of RNA to guide a 
nuclease (Cas9) to a specified site in the genome to induce a double-stranded break. An 
exogenous template is then used to modify the mutated site, thereby correcting the 
original defect in the gene. Various groups have used CRISPR/Cas9 to introduce 
dystrophin expression in vitro to immortalized DMD-derived myoblasts and in vivo to the 
mdx mouse, the most commonly used model of DMD (Iyombe-Engembe et al., 2016, 
Long et al. 2014, 2016, Nelson et al., 2016 Tabebordbar et al., 2016). An important 
aspect of the CRISPR system that renders it perhaps more useful than current exon 
skipping practices is the ability to excise a large fragment of DNA, spanning a number of 
exons. By covering the mutations in exons 45-55, CRISPR/Cas9 offers the potential to 
address over 60% of DMD cases.  
1.3.3 Cell therapy  
The chief self-renewing muscle progenitor cell is the satellite cell (SC), named for its 
location under the basal lamina. SCs are the primary physiologically relevant stem cell 
population contributing significantly to muscle regeneration (Murphy et al., 2011, Chang 
et al. 2014). When satellite cells are activated, they undergo myogenesis, differentiating 
into myoblasts that fuse with each other to form multinucleated myotubes (Figure 1.3). 
Given the ability of SCs and other muscle progenitor cells to undergo myogenesis, 
various groups are looking at these populations as ways to introduce dystrophin-
expressing stem cells into dystrophic muscle (Mendell et al. 1995, Skuk et al. 2006, 
2007). Stem cell therapy has been one of the most widely studied- and perhaps most hotly 
contested- approaches to treating DMD. Clinical trials involving muscle-specific stem 
cells have been ongoing since the 1990’s. There is evidence of donor cells present in 
recipient tissue up to 13 years post implant, suggesting the possibility for using cell 
therapy in the future (Gussoni et al. 2002, Skuk & Tremblay 2016). Although these initial 
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studies have furthered our knowledge regarding the role of various cell populations in 
regenerating lost muscle, there have been no widespread reports of any cell therapy 
having significant effects on muscle function following treatment. There are a number of 
ongoing clinical trials with estimated completion dates in 2016-2018 using various 
populations of stem cells including umbilical cord-derived mesenchymal stem cells and 
bone marrow-derived stem cells. Rita Perlingeiro’s group is currently investigating the 
efficiency of induced pluripotent stem cells to regenerate muscle in mdx mice (Filareto et 
al. 2012). This approach involves isolating skin fibroblasts from mdx mice/DMD patients, 
reprogramming them back to a pluripotent stem cell state, correcting the dystrophin 
mutation, and implanting them back into the host. This approach is attractive in that it 
uses an autologous transplant, which largely mitigates the chances of stem cell rejection 
post-implant.  
 
While cell therapy research may be promising for the future, this and other regenerative 
approaches face a significant hurdle in that they attempt to introduce dystrophin into a 
hostile, fibrotic environment that is not conducive to regeneration (Klinger et al. 2012). 
The “seed and soil” hypothesis, often referred to in cancer research, is also applicable to 
regenerative therapy for DMD. Regardless of the regenerative capacity of any specific 
cell population, its potential for reconstituting muscle is dependent on the transplantation 
environment. Given the inflammation and fibrosis that is so prominent in muscular 
dystrophy, it is not surprising that cells do not survive after transplantation. Since parents 
are often unaware their child is affected until 1-6 years of age, this pathogenesis has 
already been initiated and any therapeutic approaches would involve the presence of 
inflammation and potentially fibrosis. Thus, in addition to researching methods for 
introducing dystrophin into muscle, there is also a need to find ways to improve the 
hostile environment that will receive cell transplantation. 
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Figure 1.3: Muscle-specific stem cells known as satellite cells undergo myogenesis to 
form muscle tissue.  
Satellite cells, while present in DMD patients, are quickly exhausted and the process of 
myogenesis is insufficient to meet the demands of reconstituting muscle in patients. 
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Figure 1.4: VEGF and ANG1 play a role in angiogenesis by eliciting different 
responses upon binding to their receptors on endothelial cells.  
Upon binding to its type-2 receptor (VEGFR-2), VEGF increases endothelial pores 
through p38/MAPK signaling, allowing for extravasation of leukocytes from the blood 
into tissue. Upon activation of phospholipase C-gamma (PLC-ϒ), signaling through the 
Raf/MEK/MAPK pathway results in DNA synthesis and cell proliferation. Upon ANG1 
binding to the Tie2 receptor, vascular-endothelial (VE) cadherin increases cell-cell 
interaction for increased barrier function. ANG1 also increases vascular smooth muscle 
cell (SMC) recruitment indirectly by increasing expression of endothelial cell (EC)-
derived chemoattractants, such as platelet-derived growth factor, hepatocyte growth 
factor, and heparin-binding epidermal growth factor. Binding of both VEGF and ANG1 
to VEGFR-2 and Tie2, respectively, lead to increased cell survival through 
phosphoinositide 3-kinase (PI3K) activation. Portions of the figure adapted from 
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Ilvanainen et al. 2003; Kobayashi et al. 2006, Shibaya & Claesson-Welsh 2006, Olsson et 
al. 2006; Li et al. 2015). 
 
1.4 Vascular targeted therapy for DMD 
 
Vascular therapy has been identified as a potential treatment for DMD (Ennen et al. 
2013). Since vascular endothelial growth factor (VEGF) has long been accepted as a 
master regulator of vessel development, groups are attempting to increase its function- 
through receptor modulation or administration of the growth factor itself- to enhance the 
vasculature in animal models of DMD. VEGF exerts its effect by binding to its type II 
receptor, VEGFR2, inducing receptor dimerization, leading to phosphorylation of 
intracellular tyrosine residues (Ruch et al. 2007). Activation of VEGFR2 can lead to 
increased signalling through a variety of pathways, but the most relevant to the 
angiogenic response in endothelial cells is the RAS/RAF/MEK/MAPK pathway, 
although the details have not been fully elucidated (Meadows et al. 2001). Ras activation 
in ECs has been shown to play a role in proliferation, migration, and branching cues.  
Importantly, VEGF binding to VEGFR2 also increases vascular permeability through 
formation of endothelial pores (Garrido-Urbani et al. 2008). Although VEGF induces an 
angiogenic response, the newly formed vessels are “leaky”, lacking functional maturity, 
which may impede any enhancements to the blood flow. As such, it is hypothesized that 
use of VEGF in combination with other factors may be necessary to attain fully 
functional vessels. One factor in particular is the secreted glycoprotein angiopoietin-1 
(ANG1), a member of the angiopoietin family of growth factors. By binding to the Tie2 
receptor, ANG1 plays a vital role in endothelial remodelling (Baffert et al. 2004 & 
Thurston et al. 2005), vascular reinforcement (Gamble et al. 2000), and vessel survival 
(Cho et al. 2004). ANG1 is therefore under investigation for a range of diseases including 
sepsis and stroke (Sato et al. 2005). Given its role in promoting vascular maturity during 
both development and in adult tissue, ANG1 is a prime candidate to exert synergistic 
effects along with VEGF in dystrophic, ischemic muscle.   
17 
 
Another reason angiogenic growth factor supplementation may be beneficial to DMD 
patients is the fact that current gold standard medications may interfere with endogenous 
VEGF action. Glucocorticoids (Prednisone, Deflazacort), are the cornerstone therapy 
currently offered to DMD patients, with therapy beginning around five years of age.  
Randomized controlled trials that originated in the late 1980’s revealed a short-term 
benefit to patients receiving glucocorticoids, evidenced by improved muscle function for 
six months to two years, but long term benefits were not apparent (Mendell et al. 1989). 
Although this study occurred decades ago, glucocorticoid treatment is still prescribed 
based on these findings. One potential explanation for this lack of long-term efficacy may 
reside in the fact that glucocorticoids inhibit VEGF and MMP-2 (Ishiguro et al. 2014). 
Matrix metalloproteinase-2 (MMP-2) is a promising candidate for enhancing VEGF-
induced angiogenesis since it increases the ability of endothelial cells to degrade ECM 
components and invade through the matrix. Thus, while glucocorticoids may reduce 
inflammation, they may also be acting to reduce angiogenesis and perhaps contribute to 
the long-term progression of disease. It is possible that increasing circulating VEGF 
levels through treatment may alleviate this undesired effect of glucocorticoids and 
increase their efficacy as well.  
 
1.4.1 Vascular therapy to reduce muscle ischemia  
Proper blood delivery is vital to maintenance of healthy organs. In a highly metabolic 
tissue such as skeletal muscle, proper blood flow is crucial for delivering oxygen and 
nutrients that are in high demand, particularly during exercise and contractions required 
from day-to-day movements. The vascular response is crucial in mediating changes in 
blood flow, inducing vasodilation when there is an increased metabolic demand. Thus, in 
DMD patients in whom vasodilation is impaired, oxygen and nutrient delivery is reduced 
(Nelson et al. 2014). Although muscle ischemia is not the primary culprit responsible for 
the DMD pathology, it certainly perpetrates myonecrosis, adding to overall disease 
progression. Specifically, functional ischemia plays an integral, although not exclusive, 
role in contraction-induced muscle damage (Asai 2007). Increasing vasodilation via 
phosphodiesterase-5 (PDE-5) inhibitor, tadalafil, has been shown to lessen the extent of 
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myofiber damage in the mdx mouse (Adamo et al. 2010 Percival et al. 2012). In DMD 
patients, sildenafil, another PDE-5 inhibitor, rescues exercise-induced hyperaemia 
(Nelson et al. 2014).  These findings highlight the value of increasing blood flow in the 
poorly perfused dystrophic skeletal muscle. An important question that is still 
unanswered is whether restoring blood flow actually slows disease progression in 
dystrophic muscle. 
 
1.4.2 Vascular therapy to enhance endogenous repair 
One of the main goals of vascular therapy is to introduce a factor, or factors, that act on 
vascular cells (endothelial cells, smooth muscle cells), to increase their function in the 
vascular network. An added benefit of vascular therapy that has been elucidated since the 
early 2000’s is its effect on endogenous repair mechanisms. A number of studies have 
eloquently demonstrated that endogenous repair mechanisms are insufficient in DMD and 
animal models of the disease (Sacco et al. 2010, Dumont et al. 2015). In healthy 
individuals, muscle-specific stem cells, known as satellite cells, are largely responsible 
for this repair mechanism by regenerating new myofibers. A 2010 study by Sacco et al. 
demonstrated a reduced regenerative capacity of SCs derived from dystrophic muscle. 
Due to shortened telomere length and decreased telomerase activity, SCs in dystrophic 
skeletal muscle are unable to keep up with the self-renewal required to regenerate lost 
tissue. A 2015 study by Dumont et al. has received a great deal of attention for 
uncovering another deficient mechanism in mdx SCs. For decades, researchers have 
shown that myoblasts in culture do not express dystrophin, but this study showed, for the 
first time, that SCs do express the protein and that it is necessary for proper cell polarity. 
This polarity gives SCs important cues regarding needs for replication, activation, and 
differentiation. Thus dystrophin-deficient SCs do not receive proper environmental cues 
and therefore lack their full function. This study has paved the way for DMD to now be 
classified not only as a muscle-wasting disease, but also as a stem cell disease. Taken 
together, these studies have highlighted the need to improve endogenous repair 
mechanisms in a system where this process is quickly exhausted.  
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Viral delivery of VEGF has demonstrated its ability to improve endogenous repair in 
skeletal muscle. Following injection of recombinant adeno-associated VEGF (rAA 
VEGF), histological findings show an increase in myogenin-positive SCs. Myogenin is 
expressed early in myogenesis and is therefore a good indicator of regeneration. This 
study also demonstrated a significant increase in the number of regenerating myofibers 
compared to mdx mice receiving a control injection (Messina et al. 2007). Similar results 
were observed in a hind limb ischemia model and the glycerol and cardiotoxin models of 
muscle injury (Arsic et al. 2004). It is now well accepted that SCs express both VEGF as 
well as its receptor, VEGFR-2, and in fact, in healthy skeletal muscle, SCs account for 
the majority of VEGF and VEGFR-2 expression.  
 
1.4.3 Vascular therapy to enhance cell therapy 
 
In regards to using vascular therapy as an adjunct to other therapeutic approaches, there is 
a growing body of evidence to suggest that it may enhance the engraftment and function 
of transplanted cells. A major hurdle of current cell therapy approaches is the lack of 
survival, migration, proliferation, and function of transplanted cells. In 1977, 
Schmalbruch et al. discovered that SCs reside in close proximity to microvasculature, 
suggesting a possible role for blood vessels in directing the movement of stem cells. 
Indeed, a 1984 study by Venkatasubramanian and Solursh demonstrated that embryonic 
skeletal muscle cells migrate toward a gradient of growth factors whereas other 
mesenchymal cell types present in the limb bud do not exhibit this chemotactic 
behaviour. The finding that myoblasts migrate towards areas of existing vasculature, due 
to secretion of pro-angiogenic growth factors, has prompted researchers to investigate the 
ability of angiogenesis to aid in the migration of transplanted myoblasts. Thus, in 2001, 
Corti et al. tested the ability of various growth factors to enhance migration of C2C12 
myoblasts across an endothelial layer. Various growth factors, in particular hepatocyte 
growth factor as well as platelet-derived growth factors A and B significantly increased 
migration of myoblasts. VEGF has also been shown to increase migration of C2C12 
myoblasts and SCs in the Boyden chamber assay, an in vitro experiment used to measure 
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cell migration (Germani et al. 2003). The hypothesis that VEGF may in fact enhance cell 
transplants was put to the test in a study assessing the effects of the growth factor on 
muscle derived stem cell transplants into the mdx mouse (Deasy et al. 2009). VEGF was 
shown to increase proliferation and differentiation of the stem cells in vitro, lending 
further evidence that VEGF does not act solely on endothelial cells in the context of 
DMD treatment. Although this group reported an increase in endogenous repair, decrease 
in fibrosis, and increase in microvasculature following transplantation of VEGF-
expressing muscle stem cells, VEGF expression did not result in an increase in 
dystrophin-positive myofibers, which would be expected if these cells had indeed 
contributed to the new muscle. The authors do postulate, however, the lack of dystrophin-
positive fibers could be due to the pro-proliferative effect of VEGF on MDSCs, resulting 
in increased proliferation of these transplanted cells, but not necessarily increased 
differentiation. Interestingly, a more recent study from the same group demonstrated the 
regenerative capacity of MDSCs is reduced when VEGF signalling is inhibited (Beckman 
et al. 2013). This study and others have highlighted the beneficial effect of VEGF on cell 
transplants, but have proposed that it may be through mechanisms other than enhancing 
the engraftment of these cell populations contribute to the reconstitution of the muscle 
(Distefano et al. 2013). VEGF as a proliferative stimulus may increase the survival of 
transplanted cells, thereby allowing them to exert a paracrine effect for a larger amount of 
time, contributing to further endogenous repair in the muscle. Overall, based on the 
chemotactic effect of pro-angiogenic factors such as VEGF, future studies using 
angiogenesis as a pre-treatment for cell transplants may augment the effect of these cells 
following treatment.  
 
 
1.4.4 Limitations to current vascular therapy 
 
Given the potential of angiogenesis to enhance both endogenous repair and cell therapy 
for treating DMD, methods for increasing VEGF, a potent inducer of angiogenesis, are 
attractive. Although an impressive body of research supports the potential efficacy of 
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VEGF as a DMD drug, the majority of studies have used viral methods to deliver the 
growth factor. Although adeno-associated viruses have been used in a number of clinical 
trials and appear to be relatively safe, it is not yet clear whether the actual dose of VEGF 
expressed in the tissue could be predicted in a consistent manner. This concern is of 
special importance considering the findings that describe formation of hemangiomas 
following long-term exposure to VEGF treatment at high doses (Springer et al. 1998, Lee 
et al. 2000). Thus, it would be of particular value to deliver the growth factor at a low 
dose in a more controlled manner. 
 
The standard method for determining the effect of vascular therapy on angiogenesis is ex 
vivo histology. Elevation in expression of CD31, a marker of endothelial cells, is the most 
commonly used measurement of angiogenesis. Since CD31 is also a marker of 
macrophages and neutrophils, extreme care must be taken to ensure that measurement of 
this marker excludes any type of inflammatory cells present in dystrophic muscle. 
Further, CD31 marks the endothelial layer, but it does not mark functionally mature 
vessels. Thus, in addition to CD31, assessing alpha-smooth muscle actin expression in 
vascular smooth muscle cells may demarcate vessels that confer functional benefit to the 
muscle. Much like CD31 staining, though, extreme care must be taken to ensure 
distinction is made between αSMA that marks blood vessels compared to that which 
marks myofibroblasts.  Previous studies that have reported changes in either CD31 or 
αSMA do not elaborate on the methods used to quantify expression of these markers 
histologically. Even taking these limitations into account, very few studies go beyond 
histological findings to assess the functional efficacy of vascular-targeted therapy. Thus, 
there is little evidence, to date, that VEGF, with or without ANG1, actually affects 
functional perfusion. Therefore, it is absolutely critical to determine whether or not these 
factors may affect perfusion and correlate those findings to conventional histological 
data.  
 
Transplant studies using cells expressing VEGF have demonstrated a decrease in fibrosis 
following treatment. While these findings may suggest an anti-fibrotic role of VEGF in 
dystrophic muscle, this is an important assumption that has not yet been rigorously tested. 
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The importance of fibrosis in DMD has gained more attention in recent years and any 
therapeutic approach under investigation should specifically assess its effect on fibrosis 
in this disease. To do so, an appropriate animal model, one that develops significant 
fibrosis, must be used. There is currently a lack of data to support the anti-fibrotic role of 
VEGF in DMD. Given that VEGF has been shown to exacerbate extracellular matrix 
(ECM) deposition in other fibrotic diseases such as scleroderma and idiopathic 
pulmonary fibrosis (Maurer et al. 2014 & Hostettler et al. 2014), it is plausible that VEGF 
may also exert a pro-fibrotic response in DMD. Testing the effect of VEGF at an 
appropriate stage of disease progression and in a relevant model should be done prior to 
moving to larger animal models and, certainly, prior to clinical studies.  
 
1.5 Functional assessment of therapeutic efficacy 
While vascular-targeted therapy offers significant potential for the treatment of DMD, 
current research is hindered by an important limitation. The standard method for 
assessing the effect of vascular therapy is through invasive muscle biopsies that may 
themselves contribute to further disease progression (Forbes et al. 2013; Triplett et al. 
2014). In addition to the invasive nature of muscle biopsies, information gleaned from 
this tissue is limited to histological (H&E, Masson’s Trichrome stains), biochemical, and 
molecular (western blotting, gene expression) analyses that preclude any sort of 
longitudinal, functional assessment.  DMD manifests as a very heterogeneous disease 
affecting certain muscle groups differently (Forbes et al. 2013; Triplett et al. 2013). In 
fact, some muscle groups appear nearly unaffected in DMD. Depending on the tissue 
region selected for biopsy, this sample may drastically over or underestimate the true 
extent of therapeutic efficacy in the patient. Thus, there is a critical need for ways to 
noninvasively assess disease progression and subsequent efficacy of therapeutic 
interventions.  
1.5.1 Laser Doppler Imaging 
Laser Doppler imaging (LDI) utilizes infrared light to monitor the movement of blood 
cells in the microvasculature. Since it is an optical technique, it is primarily used to 
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monitor blood flow in superficial tissues, such as in skin, to assess burns and the extent of 
fibrosis in systemic scleroderma, as well as intraoperatively during brain surgery. 
Researchers have used it to assess blood flow in a rodent hind limb ischemia model in 
rodents. In this model, an incision is made in one hind limb and the femoral artery is 
occluded, inducing ischemia in that limb. LDI is then used to monitor re-perfusion of that 
muscle over time.  In recent years, groups have used the hind limb ischemia model to 
assess angiogenic capabilities in mdx mice (Palladino et al. 2013) and the effect of cell 
therapy on blood flow (Brenes et al. 2012). While these studies have tremendous value in 
demonstrating functional changes in the disease with and without a therapeutic 
intervention, there are inherent limitations to the use of LDI to assess therapy in DMD 
research. Depth of penetration is minimal, with the average depth capable of imaging via 
laser Doppler being 1mm  (Rajan et al. 2008), although this value is strongly dependent 
on wavelength. This limited penetration makes LDI suitable for skin and superficial 
imaging, but not suitable for deeper tissues without invasive surgery. The degree of 
ligation is also a source of variability in inducing ischemia, opening up a potential source 
of misinterpreted results. Lastly, and perhaps most importantly, the hind limb ischemia 
model is an acute, invasive technique, suitable for animal research only. Although LDI 
studies provide valuable insights into functional effects of therapeutic intervention, a 
number of modifications would be required to use LDI to assess vascular therapy in 
patients. It would be invaluable to use a functional imaging tool that could be performed 
in both preclinical animal models as well as patients to better elucidate what differences 
may exist in treatment responses. Further, in a disease characterized by inflammation and 
constant muscle degeneration, studying therapeutic efficacy following an additional 
surgical injury may introduce a source of confounding results.  
1.5.2 Non-invasive imaging 
While the use of LDI in the hind limb ischemia model offers a number of advantages for 
basic researchers, it is not a practicable option for patient studies. The potential benefits 
that non-invasive imaging offers for both monitoring disease status and therapeutic 
outcome are numerous and may change our understanding of DMD progression and 
treatment. From the perspective of a patient, non-invasive imaging would eliminate the 
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need for painful muscle biopsies, which are the typical method of assessing muscle 
damage. The biopsy process itself may also induce further damage to already injured 
muscle. From the perspective of a researcher, non-invasive imaging allows for a more 
global analysis of what is happening in vivo, an advantage not offered by ex 
vivo histological analyses. It has also been suggested that changes observed non-
invasively may precede changes in physiological outcome, i.e. muscle contractile 
strength and endurance (Ahmad et al. 2010), which is important when considering the 
timing of therapeutic intervention. It should be noted, however, that non-invasive 
imaging is not yet able to definitively diagnose DMD in patients (Grounds et al. 2008 
Kuru et al. 2013). While new blood tests for detecting specific mutations in the 
dystrophin gene are being developed (Kim et al. 2010), it would be advantageous to 
investigate the use of non-invasive imaging for diagnostic purposes as well. Regardless, 
computed tomography (CT), magnetic resonance imaging (MRI), and positron emission 
tomography (PET) may be viable options to non-invasively assess disease progression 
and therapeutic efficacy. 
1.5.2.1 DCE-CT 
X-ray computed tomography (CT) technology utilizes computed-processed X-rays to 
produce a three-dimensional image of the internal structures of an object. Dense tissues 
such as bones will attenuate an X-ray more than tissues that are composed largely of 
water or air. CT resolutions between tissue densities allow researchers to distinguish 
between tissues that vary by only 1% in their densities, making it an ideal tool to image 
fat and muscle tissue (Gellerich et al. 1990; Goodpaster et al. 2000).  Given these 
characteristics, CT has been in use since the 1980’s to monitor structural changes in 
dystrophic skeletal muscle, becoming a gold standard in assessing muscle degeneration.  
While dynamic contrast enhanced CT (DCE-CT) has not been widely used in the DMD 
research field, it has made significant contributions to the diagnosis and treatment 
strategies of other diseases. DCE-CT has significantly improved outcomes for stroke 
patients by helping to distinguish stroke sub-types, which has enhanced patient quality of 
life and lessened the economic burden associated with poorly managed stroke treatment. 
There are some important limitations to using CT to assess muscle involvement in DMD 
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patients, which may explain the lack of routine clinical use. First, there are concerns with 
x-ray exposure to humans; repeated scans during a longitudinal study may be particularly 
unsafe for pediatric patients (Brenner et al. 2001). Current research is attempting to 
implement dose reduction methods using various software and hardware techniques that 
may reduce radiation dose by 2–3 fold, making it more suitable for use in young patients 
(Lee et al. 2010). Additionally, most CT methods are unable to distinguish between 
connective tissue and muscle, which makes it difficult to assess extent of fibrosis, another 
hallmark of DMD (Liu et al. 1993; Nakayama et al. 2013). Dynamic contrast-enhanced 
CT (DCE-CT) may address this issue by providing measurements of perfusion in skeletal 
muscle. Since fibrotic tissue is largely under perfused, blood flow to those areas is limited 
and thus may be detected via DCE-CT. The use of a radiopaque contrast agent, such as 
iodine with a high atomic number, is also ideally suited to monitor changes in muscle 
ischemia that are inherent to disease progression in DMD. DCE-CT has been used to 
assess changes in blood flow in the mdx mouse following exercise and to monitor disease 
progression in a severely affected model of DMD (Ahmed et al. 2011). While these 
results point to the usability of DCE-CT in murine models of DMD, no study to date has 
used this tool to assess therapeutic intervention.  
1.5.2.2 MRI and PET 
Magnetic resonance imaging (MRI) is an ideal imaging modality for visualizing the 
anatomy of soft tissue within the body, thus offering many potential benefits for use in 
assessing muscle pathogenesis in both animal models of DMD, DMD patients and other 
patients suffering from a broad spectrum of myopathies (Lamminen et al. 1990, a,b; Liu 
et al. 1993). Magnetic resonance imaging (MRI) involves placing a subject in a strong 
magnetic field, which results in the alignment of hydrogen nuclei that are part of water 
molecules. When an external radio wave is applied to the subject in the magnetic field, 
some of the nuclei are excited. After relaxing from this excited state, the released energy 
produces small radio signals, or pulses, that are detected by the scanner, in both time and 
space. The time it takes for the longitudinal or transverse excitations to relax are referred 
to as T1- and T2-relaxation times, respectively. Imaging techniques focused on transverse 
relaxation times produce images with areas of high water content appearing dark (weak 
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signal strength), and areas of higher fat content appearing bright (strong signal strength). 
To this end, MRI has been utilized to distinguish healthy versus dystrophic muscle in the 
mdx mouse (McIntosh et al. 1998). Specifically, T2-weighted images illustrate that 
degenerating muscle in mdx mouse hind limbs appear more heterogeneous on an MR 
image compared to hind limb musculature of a wild-type mouse, which appears largely 
homogeneous; higher T2 values were attained in control muscles and these regions of 
interest appeared “lighter” than in the degenerating muscle in mdx mice. Histologically, 
the “dark” areas on a T2 map were found to correspond to areas of inflammation and 
macrophage infiltration in dystrophic muscle lesions, as validated histologically. 
Additionally, some areas on a T2 map of dystrophic hind limbs exhibited an intense 
signal, indicating the presence of fatty infiltrate in the mdx mouse that was not present in 
healthy wild-type hind limb musculature (Dunn et al. 1999). Recent work by 
Vandenbourne and colleagues, confirms the use of T2 mapping to assess changes in 
skeletal muscle of the lower extremities in DMD patients aged 5–15. Specifically, this 
group confirmed that T2 values are elevated in lower limb muscles of DMD patients 
versus healthy, age-matched control subjects, including younger subjects between the 
ages of 5 and 8. Interestingly, these differences in T2 values correlated well with 
functional tests of muscle contractile strength tests in these individuals. Another recent 
study from 2010 reported the use of T2 mapping to examine the effect of corticosteroid 
treatment—the current gold standard therapy to inhibit/reduce inflammation—in DMD 
patients relative to both untreated and healthy patients. While patient compliance is 
always a potential issue given the age of DMD patients, MRI may be safely repeated and 
confers no pain to the individual. Furthermore, MRI does not involve ionizing radiation, 
making it an attractive tool for pediatric patient use. Taken together, these studies provide 
compelling evidence that MRI may be a valuable tool for providing information on 
global changes in muscle composition as disease progresses, with or without the use of 
therapeutic interventions. 
While MRI and CT are useful for their detailed anatomical data and high resolution, PET 
imaging may offer more information in regards to muscle function in animal models and 
in DMD patients. PET involves the use of a radiolabeled substance that will emit 
positrons after injection into the body. When a positron collides with a nearby electron, 
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two 511 keV photon are created.  Detectors in the PET scanner capture this coincidence 
event allowing for localization of the collision. Thus, depending on the radiolabeled 
substance, various types of cells and tissues can be imaged. The most widely used 
substance in patients today, mainly as a standard diagnostic imaging tool for cancer is 
fluorine[18]-labeled fluorodeoxyglucose (18F-FDG), a glucose analog. Cells that express 
the GLUT-1 glucose transporter, mainly metabolically active cells, take up 18F-FDG. 
While some studies have used FDG-PET for assessing muscular dystrophy-related 
cardiomyopathy in patients (Quinlivan et al. 1996), it has yet to be assessed in significant 
studies of skeletal muscle metabolism in DMD patients. There is strong evidence that 
FDG-PET will be a useful tool for monitoring inflammation in myopathies as indicated 
by a progressive increase in FDG uptake compared to wild-type controls (Tateyama et al. 
2015, Al Nahhas et al. 2011). 
  
While PET imaging may be a promising avenue for longitudinally assessing muscle 
degeneration and therapeutic interventions, there are a few limitations that must also be 
considered. First, more work needs to be conducted to determine the utility of FDG as a 
radiolabel for inflammatory cells. Although inflammatory cells express the GLUT-1 
receptor, muscle cells, which are highly metabolic, express this receptor as well. As such, 
changes in FDG uptake could be due to changes in inflammation or due to changes in 
muscle metabolism. Thus, more proof-of-principle studies will be required prior to using 
FDG in the context of DMD. Similarly, although MRI offers considerable advantages for 
imaging skeletal muscle, there are still drawbacks to using this modality. Hence CT is 
most optimal for preclinical studies in DMD research. Imaging time is significantly 
longer for MRI compared to CT, which is a drawback for both pediatric patients as well 
as preclinical studies in mice whereby a mouse would need to be anesthetised for hours 
compared to just minutes for CT. In terms of feasibility, the cost of an MRI scan is much 
higher than for a CT scan and, for clinical studies, claustrophobia and patient compliance 
would be a more significant issue using MRI. 
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1.6 Thesis hypotheses and specific objectives 
 
1.6.1 Hypotheses 
A combination of VEGF and ANG1, but not VEGF alone, will enhance skeletal muscle 
perfusion in a murine model of muscular dystrophy and this effect can be measured non-
invasively using dynamic contrast-enhanced computed tomography. 
 
1.6.2 Specific objectives 
Chapter 2 
i) Investigate histopathological features in the mdx, mdx/utrn+/- and dko mice 
and compare those findings to C57BL/10 mice to determine the suitability of 
each as a model of Duchene muscular dystrophy.  
Chapter 3 
ii) Determine whether VEGF elicits a pro-fibrotic response in fibroblasts derived 
from a murine model of DMD.  
Chapter 4 
iii) Assess the effect of VEGF alone or in combination with ANG1 on the 
microenvironment (i.e. vasculature, collagen deposition, and inflammatory 
infiltration) in dystrophic murine skeletal muscle.  
iv) Employ dynamic contrast-enhanced computed tomography (DCE-CT) to 
determine if ex vivo changes in angiogenic, inflammatory, and fibrotic 
markers observed in aim 3 correlate with functional changes in skeletal 
muscle perfusion.  
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2 Skeletal muscle fibrosis in the mdx/utrn+/- mouse 
validates its suitability as a murine model of DMD 
 
2.1 Chapter Summary 
The mdx mouse and X-linked canine muscular dystrophy are the two most widely used 
animal models of DMD. Given the ethical concerns regarding the use of canine models 
for basic research, the mdx mouse is by far the most commonly cited model in preclinical 
studies. Although the dystrophin-null mdx mouse genotypically mimics the human 
disease, recent focus on the importance of fibrosis in DMD highlights the importance of 
this aspect be represented in any suitable model. Since our research focus on the use of 
angiogenic factors as a treatment for DMD and other studies have suggested the ability of 
some angiogenic growth factors to induce fibrosis, using a model that is more prone to 
fibrosis is absolutely critical in the accurate assessment of therapeutic side effects. The 
presence of utrophin, a dystrophin analogue, inversely correlates with disease 
progression. Therefore, the mdx (utrophin +/+), heterozygous (mdx/utrn+/), and double 
knockout (mdx/utrn-/-) mice all represent varying degrees of disease severity. In the 
present study, we compare disease pathology in the mdx mouse with the other two 
models.  Importantly, we also compare disease pathology to the C57BL/6 wild type 
mouse to provide an accurate margin for classifying fibrotic from non-fibrotic muscle 
tissue. Using extent of collagen deposition and number of centrally nucleated myofibers 
as indicators of disease severity, we show that the heterozygous mdx/utrn+/- mouse is a 
superior model to the mdx mouse since extent of collagen deposition is greater by 7-8 
weeks of age compared to the wild-type or mdx models. This study established the best 
model and age to incorporate in the subsequent studies described in this thesis.  
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2.2 Introduction 
Treatment strategies for Duchenne muscular dystrophy (DMD), a severe neuromuscular 
degenerative disorder, have been ongoing for decades with little significant long-term 
efficacy reported (Pichavant et al. 2011). While scientific and technological 
advancements have enhanced patient quality of life, the disease remains invariably fatal. 
The majority of current research into treating DMD involves the restoration of the protein 
dystrophin, which is absent or non-functional in these patients. Of these, a number of 
studies in DMD patients have used cell therapy to replace dystrophin, reporting an 
increase in dystrophin-positive myofibers (Mendel et al. 1995; Skuk et al. 2004, 2006, 
2007; Rodino-Klapac et al. 2013; Cirak et al. 2012; Seto et al. 2014). While these studies 
have successfully reintroduced the protein to dystrophic skeletal muscle, improvements 
in function have been limited. A recent study by Hogrel et al. reported a potential long-
term effect of a myoblast transplant into an affected female carrier of the dystrophin 
mutation. Although long-term functional effects could not be definitively concluded from 
this study, the results suggest beneficial effects of cell therapy (Hogrel et al. 2013). To 
date, the most commonly used murine model to test cell replacement and other strategies 
in a pre-clinical setting has been the mdx mouse, which lacks dystrophin due to an X-
linked mutation in its gene (Partridge et al. 1989; Hindi et al. 2013). Although the mdx 
mouse is a genetic homolog of the human disease, it has been shown that this model does 
not mimic the pathology observed in patients because up-regulation of utrophin, a 
dystrophin analogue, partially compensates for the absence of the cytoplasmic protein 
(Grady et al. 1997). Additionally, the longer telomere length present in inbred laboratory 
mice confer a greater regenerative capacity of muscle progenitor cells in these animals 
compared to human skeletal muscle (Sacco et al. 2010). As a result of these differences, 
the disease does not manifest severely in mdx mice.  Specifically, fibrosis, a hallmark 
feature of DMD in patients, is not overt in mdx mice (Desguerre et al. 2014). A lack of 
dystrophin in skeletal muscle leads to decreased sarcolemma integrity, which causes an 
increase in cell membrane permeability. As a result, an influx of calcium ions causes 
increased protein degradation that eventually leads to muscle cell death. Inflammatory 
cells that infiltrate the site of necrosis are a rich source of transforming growth factor beta 
(TGFβ). TGFβ then exerts its pro-fibrotic effect on fibroblasts, which then increase 
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production of extracellular matrix (ECM) proteins. An excessive amount of ECM 
production leads to the eventual onset of fibrosis (Desguerre et al. 2009). The fact that 
DMD patients develop severe fibrosis whereas mdx mice do not may, in part, explain 
why treatments performed in murine studies have been ineffective in human trials. 
Fibrosis limits the amount of available muscle tissue to target with stem cell, gene or drug 
therapy (Bernasconi  et al. 1999). Thus, use of an appropriate model that more accurately 
reflects the histopathology of DMD fibrosis may better direct current research. Recent 
advances in exon-skipping have highlighted the importance of a suitable murine model in 
pre-clinical studies. In 2010, Goyenvalle demonstrated an increase in dystrophin 
expression in severely affected mice lacking both utrophin and dystrophin following 
multiple injections with a morpholino oligomer targeted to exon 23 of the dystrophin 
gene (Goyenvalle et al. 2010). Two years later, the same group modified their protocol to 
use an adeno-associated virus vector containing a small nuclear RNA specific to exon 23. 
A single treatment was sufficient to restore dystrophin in all muscles examined, including 
heart tissue, and dramatically increased life expectancy from 10 to 50 weeks of age 
(Goyenvalle et al. 2012). These studies have been crucial in highlighting the need for 
inclusion of a more accurate DMD mouse model with which to assess the efficacy of 
therapeutic strategies. 
Although utrophin-dystrophin-deficient (dko) mice were generated in 1997, they are 
scarcely used in current studies, perhaps in part due to their severe disease phenotype, 
which makes them difficult to include in longitudinal studies. While a select number of 
research groups have used this severely affected mouse model, the predominant model 
used in today’s research lab is still the mdx mouse. A few studies have suggested that 
haploinsufficiency of the utrophin gene (mdx/utrn+/-) may provide a more appropriate 
murine model of DMD (Huang et al. 2011). For example, it has been shown that 
diaphragm and quadriceps muscles of mdx/utrn+/- mice become fibrotic as early as 3 and 
6 months of age, respectively (Zhou et al. 2008). Many studies involving murine models 
of DMD have used mice younger than 6 months of age, thus the purpose of this study 
was to investigate extent of fibrosis in the mdx/utrn+/- mouse at an earlier age to 
determine its suitability as a more accurate representation of the human pathology. 
Additionally, since quadriceps and diaphragm muscles were the only groups examined in 
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the aforementioned study, we focused our study on the gastrocnemius muscle as it has 
often been used as a site of cell implant (Beckman et al. 2013). In the present study, we 
examine extent of fibrosis and muscle regeneration in 8 week-old mice as well as aged 10 
month-old mice and provide a comprehensive analysis of these parameters in various 
skeletal muscles that are used in DMD research.     
 
2.3 Materials and Methods 
2.3.1 Animal Care and Ethics Statement 
Experiments were performed at The Lawson Health Research Institute at St. Joseph’s 
Health Care (SJHC) in London, Ontario. Female C57BL/6 mice (5-7 weeks old upon 
arrival) were purchased from Charles Rivers and mdx/utrn+/- mice, originally generated 
by Dr.’s Mark Grady and Josh Sanes (Washington University, St. Louis) (Grady et al. 
1997), were generously provided to us by Dr. Robert Grange (Virginia Polytechnic and 
State University) and maintained in the Animal Care Facility at SJHC. Colonies were 
maintained under controlled conditions (19-23˚C, 12 hour light/dark cycles) and allowed 
water and food ad libitum. 7 to 8 week-old and 10 month-old male and female C57BL/6, 
mdx and mdx/utrn+/- mice were used in this study. Only 7-8 week-old dko mice were 
used since these mice do not tend to live past 20 weeks of age. For comparison of various 
skeletal muscles, twelve week-old mdx/utrn+/- male and female mice were used. All 
procedures involving animal experiments were carried out in strict accordance with the 
Canadian Council on Animal Care (CCAC) and were approved by the Animal Use 
Subcommittee at Western University. 
2.3.2 Genotyping 
Genomic DNA from tail snips or ear notch tissue was used for genotyping. Briefly, ear 
notch tissue was lysed in a proteinase K solution at 50° C overnight. DNA was diluted 
appropriately and polymerase chain reaction was used to amplify the utrophin gene using 
Platinum Taq polymerase. Presence of the utrophin gene was detected using the 
following set of primers (Sigma): 5’-TGCAGTGTCTCCAATAAGGTATGAAC-3’, 5’-
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TGCCAAGTTCTAATTCCATCAGAAGCTG -3’ (forward primers) and 5’-
CTGAGTCAAACAGCTTGGAAGCCTCC-3’ (reverse primer). 
2.3.3 Tissue Preparation and Histology 
For tissue collection, mice were sacrificed via gas euthanasia. Diaphragm and 
gastrocnemius (GM) muscles from 8 week-old and 10 month-old mice were dissected 
and immediately fixed in formalin for 24-48h and embedded in paraffin. For a more 
comprehensive analysis of disease manifestation in mdx/utrn+/- mice, diaphragm, 
quadriceps, soleus, tibialis anterior (TA) and gastrocnemius (GM) muscles were similarly 
isolated from 12 week-old mdx/utrn+/- mice. Extreme care was taken to ensure muscles 
were embedded in the same orientation across each muscle group. Tissue blocks were 
sectioned at 5um thickness and dried in an oven at 37˚C overnight. To achieve 
representative sections from the whole muscle tissue, serial sections were taken every 20 
slices, except for the diaphragm muscle where serial sections were taken every 3 slices. 
Tissue sections were then deparaffinised and rehydrated in a series of xylene and ethanol 
washes to prepare them for subsequent Masson’s Trichrome staining for collagen content, 
or haematoxylin and eosin staining to visualize regenerating myofibers. Serial sections 
were used for the two staining methods to ensure that analysis of both collagen content 
and muscle regeneration referred to the same samples. Following the staining step, slides 
were dehydrated, washed in xylene and mounted with Permount mounting medium.   
2.3.4 Microscopy and Image Analysis 
Histological images were acquired on a Zeiss Axioscope microscope under a 20x 
objective using Northern Eclipse software. Non-overlapping fields of view of the entire 
tissue were taken for each section. Five sections were imaged per tissue. For assessment 
of myofiber damage, percentage of centrally located nuclei was used as an indication of 
regeneration. All fields of view containing cross-sectional myofibers were imaged and 
manually analyzed. Collagen content was assessed across the entire tissue slice and 
automatically quantified using an in-house colour thresholding algorithm written in 
MATLAB 2010a (Mathworks, Natick, MA, USA). Briefly, all images were transformed 
into Lab colour space allowing the isolation of the colour and lightness components of 
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each pixel. A k-means clustering algorithm was then applied to the colour components of 
each individual image to partition the pixels into groups of relatively ‘red’ or ‘blue’ 
colour values (Appendix A). A uniform threshold was applied to all images to mask 
regions with high lightness (appearing as white). Finally, morphological closing 
operations were performed on the ‘red’ and ‘blue’ regions to fill any gaps less than 3 
pixels in radius. The percent of collagen present in each image was calculated as the area 
of the remaining ‘blue’ region divided by the area of the entire image. Automatic 
thresholds were manually verified with labeled colour overlays on the original histology 
images to ensure that collagen presence was accurately identified. 
2.3.5 Statistical Analysis 
For quantified images, a one-way ANOVA was performed followed by Tukey’s post-hoc 
test to determine difference between groups using GraphPad Prism. Differences between 
groups were considered significant at a p-value less than 0.05 (n=3 for wild-type and dko 
mice and n=5 for mdx and mdx/utrn+/- mice).  
2.4 Results 
2.4.1 Fibrosis is present at 10 months of age in mdx/utrn+/-, but 
not mdx, GM muscle 
At ten months of age, mdx gastrocnemius (GM) muscle did not differ in collagen content 
compared to GM muscle of wild-type mice (Figure 2.1). In contrast, haploinsufficiency 
of utrophin led to significant collagen deposition in GM tissue of aged mdx/utrn+/- mice 
(mean±SD: 12.76%±3.06, p=0.0033). There was no significant difference in collagen 
deposition between mdx and mdx/utrn+/- GM muscle. Although GM muscles of aged 
mdx mice did not show significant fibrosis compared to healthy wild-type controls, there 
was a large proportion of centrally-located nuclei in the myofibers indicative of muscle 
regeneration in both mdx (70.06%±7.6) and mdx/utrn+/- (58.86%±6.7) mice, respectively 
(p<0.0001, Figure 1D-F). 
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Figure 2.1: Muscle pathology in 10 month-old GM muscles of wild-type, mdx and 
mdx/utrn+/- mice.  
Extent of total collagen staining (blue) in 10 month-old wild-type (A), mdx (B) and 
mdx/utrn+/- (C) GM muscle was used as a marker of fibrosis. Proportion of centrally 
nucleated fibers in the same tissues (D, E, and F) was measured to assess extent of 
regeneration. Quantification of total collagen staining (G) and proportion of centrally-
nucleated myofibers (H) is represented as the mean +SD. ** represents p<0.01, and *** 
represents p<0.001 (scale bar=100μm). 
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2.4.2 DMD-associated fibrosis in present in both aged mdx and 
mdx/utrn+/- diaphragm muscle 
Both mdx and mdx/utrn+/- diaphragm muscles were significantly fibrotic in ten month-
old mice compared to age-matched wild-type controls (Figure 2A-C, p=0.026), indicated 
by an approximate 2.5 fold increase in collagen content. Both mdx and mdx/utrn+/- 
diaphragm muscle revealed a significantly higher percent of centrally located nuclei 
(34.65%±4.4 and 32.45%±5.6, respectively) compared to the age-matched wild-type 
mice (p<0.0001). There was no significant difference in number of centrally nucleated 
myofibers between mdx and mdx/utrn+/- mice (Figure 2.2). 
2.4.3 Young mdx/utrn+/- and dko, but not mdx, GM muscle 
develops fibrosis compared  to healthy GM muscle 
Fibrosis was assessed in 8 week-old GM muscles of wild type, mdx, mdx/utrn+/- and dko 
mice (Figure 2.3). There was no observed fibrosis in mdx GM (3.38%±0.9) compared to 
wild-type GM (3.40 ±0.2). There was a significantly higher amount of collagen 
deposition in mdx/utrn+/- GM (7.28%±2.2) compared to healthy wild-type and mdx 
tissue; however this difference was not significant between GM muscles of dko mice 
(9.49%±1.5). Overall, quantification of collagen content indicates that fibrosis is absent 
in wild-type and mdx GM muscle, but present in mdx/utrn+/- and dko GM muscle at a 
young age (p=0.0003). Muscle regeneration was significantly higher in all three murine 
models of DMD compared to the wild-type controls (Figure 3E-H). The proportion of 
centrally located nuclei did not differ, however, between mdx (50.41%±18.2), 
mdx/utrn+/- (49.78%±12.0) and dko GM muscle (45.44%±4.7, p=0.0007).  
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Figure 2.2: Muscle pathology in 10 month-old diaphragm muscles of wild-type, mdx 
and mdx/utrn+/- mice.  
Extent of total collagen staining (blue) in 10 month-old wild-type (A), mdx (B) and 
mdx/utrn+/- (C) diaphragms was used as a marker of fibrosis. Proportion of centrally 
nucleated fibers in the same tissues (D, E, and F) was measured to assess extent of 
regeneration. Quantification of total collagen staining (G) and proportion of centrally-
nucleated myofibers (H) is represented as the mean +SD. * represents p<0.05 and *** 
represents p<0.001 (scale bar=100μm). 
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Figure 2.3: Muscle pathology in 8 week-old GM muscles of wild-type, mdx, 
mdx/utrn+/- and dko mice.  
Extent of total collagen staining (blue) in 8 week-old wild-type (A), mdx (B), mdx/utrn+/- 
(C) and dko (D) GM muscles was used as a marker of fibrosis. Proportion of centrally 
nucleated fibers in the same tissues (E, F, G, and H) was measured to assess extent of 
regeneration. Quantification of total collagen staining (I) and proportion of centrally-
nucleated myofibers (J) is represented as the mean +SD. * represents p<0.05, ** 
represents p<0.01, and *** represents p<0.001 (scale bar=100μm). 
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2.4.4 Fibrosis is present in diaphragm muscle at a young age in all 
three murine models of DMD 
Collagen content in the diaphragm muscle was not determined to be significantly 
different between mdx mice (11.04%±2.3) and the two more severely affected animal 
models or between healthy wild-type and mdx mice (Figure 4A-D). Collagen deposition 
was significantly higher in the diaphragm of both dko (14.17%±4.4) and mdx/utrn+/- 
(13.32%±2.5) mice at 8 weeks of age compared to age-matched wild-type diaphragm 
muscle (7.1%±0.3, p=0.0235). Myofiber regeneration was significantly higher in the 
diaphragm muscles of mdx (41.48%±6.6) mdx/utrn+/- (39.39%±10.18) and dko 
(30.95%±6.4) mice compared to diaphragm muscle in wild-type mice (Figure 2.4, 
p<0.0001).  
2.4.5 Extent of fibrosis differs between muscle groups in the 
mdx/utrn+/- mouse 
Diaphragm, quadriceps, soleus, tibialis anterior (TA) and gastrocnemius (GM) muscles 
were analyzed from 12 week-old mdx/utrn+/- mice (Figure 2.5). Collagen content in 
diaphragm muscle was significantly higher than all other muscles assessed (p<0.0001). 
Both the quadriceps (8.31%±0.1) and GM muscles (9.89%±2.4) were higher in collagen 
content than the soleus muscle (2.80%±1.0) at this age. Extent of fibrosis was not 
significantly different in the TA muscle (5.85%±1.1) compared to the quadriceps, GM or 
soleus muscles. Myofiber regeneration, indicated by centrally located nuclei, was 
significantly higher in all four lower limb muscles compared to myofibers in the 
diaphragm, which only had 35.1% of myofibers in a regenerative state (p<0.0001).  
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Figure 2.4: Muscle pathology in 8 week-old diaphragm muscle of wild-type, mdx, 
mdx/utrn+/- and dko mice.  
Extent of total collagen staining (blue) in 8 week-old wild-type (A), mdx (B), mdx/utrn+/- 
(C) and dko (D) diaphragms was used as a marker of fibrosis. Proportion of centrally 
nucleated fibers in the same tissues (E, F, G, and H) was measured to assess extent of 
regeneration. Quantification of total collagen staining (I) and proportion of centrally-
nucleated myofibers (J) is represented as the mean +SD. * represents p<0.05, ** 
represents p<0.01, and *** represents p<0.001 (scale bar=100μm) 
53 
 
 
Figure 2.5: Comparison of histopathology of 12 week-old mdx/utrn+/- diaphragm, 
quadriceps, soleus, tibialis anterior and gastrocnemius muscles.  
Extent of collagen staining (A,C,E,G,I) and muscle regeneration (B,D,F,H,J)  in 12 week-
old mdx/utrn+/- mice. Quantification of total collagen staining (K) and centrally-
nucleated myofibers (CNF, L) is represented as the mean ±SD. * represents p<0.05, ** 
represents p<0.01, and *** represents p<0.001 (scale bar=100μm). TA= tibialis anterior, 
GM= gastrocnemius. 
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2.5 Discussion 
Fibrosis is a hallmark feature of Duchenne muscular dystrophy (DMD), yet the most 
widely- used murine model for the disease, the mdx mouse, does not model this aspect of 
DMD until an advanced age (Desguerre et al. 2002). Consistent with previous reports 
(Ishizaki et al. 2008), this study demonstrates that while the diaphragm muscle becomes 
fibrotic in aged mdx mice hind limb muscle does not. Many studies that investigate the 
potential use of stem cell or gene therapy for DMD use hind limb muscles, such as the 
gastrocnemius muscle (GM), for sites of injection (Qu-Petersen et al. 2002). Here, we 
demonstrate that neither young nor aged mdx mice develop a significant amount of 
fibrosis in the GM muscle compared to healthy wild-type controls of the same age. The 
fact that mdx mice lack this excessive deposition of extracellular matrix proteins may 
lead researchers to overestimate treatment efficacy in this murine model since there is a 
lack of environmental hostility when testing their therapeutic agents. Alternatively, the 
mdx/utrn+/- mouse exhibits hind limb fibrosis at 10 months of age. Interestingly, a large 
proportion of regenerating myofibers, indicative of damage, was measured in both aged 
animal models. Centrally located nuclei are a hallmark of muscle regeneration, and are 
often used as an indicator of muscle pathogenesis (Anderson et al. 1987). Indeed, while 
centric nuclei are prominent in the mdx mouse model of DMD, other aspects of the 
disease in humans, particularly fibrosis, are not phenocopied. This may be due, at least in 
part, to the up regulation of utrophin in the mdx mouse. As a result, overall muscle 
damage is significantly less in mdx mice than in utrophin heterozygotes and double 
knockout animals. Interestingly, we have further shown that in muscle tissues exhibiting 
higher levels of collagen (e.g. diaphragm), proportions of centric nuclei are lower. In 
contrast, the GM muscle in mdx mouse exhibits a significantly higher number of centric 
nuclei, but little deposition of collagen. These findings are consistent with earlier reports 
hypothesizing that centrally-nucleated myofibers are more resistant to mechanical stress, 
which may in part explain for the differences in the pathology observed in diaphragm 
versus hind limb skeletal muscles (Narita et al. 1999). 
Since DMD manifests at a young age in humans and because most DMD research is 
performed in younger animals, we also investigated extent of fibrosis in eight week-old 
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mice. Although the GM muscles in young mdx mice are in a regenerative state as 
evidenced by the presence of centrally located nuclei, we did not measure a significant 
degree of fibrosis in them. In comparison, there was a higher level of collagen measured 
in both moderately affected mdx/utrn+/- and severely affected dko mice relative to their 
healthy counterparts, suggesting fibrotic progression in these animals. Upon validating 
the mdx/utrn+/- mouse as more fibrotic compared to mdx littermates, we sought to 
further characterize extent of fibrosis in various muscle groups isolated from the 
heterozygous mouse model. As expected, the diaphragm muscle was highly fibrotic 
compared to the quadriceps, soleus, tibialis anterior and GM muscles. In comparison, 
there was no detectable difference in collagen deposition between the quadriceps, TA or 
GM muscles; this is an important finding considering that all three muscles are used in 
current research and therefore should display signs of fibrosis (Fletcher et al. 2006, 
Church et al. 2014). Interestingly, we measured a lower amount of collagen content in the 
slow-twitch soleus muscle than the fast-twitch quadriceps and GM muscles.  The fact that 
fibrotic progression is not equal between individual skeletal muscles is an important 
factor to consider in future studies. 
Taken together, this study supports previous literature that argues for the replacement of 
the mdx mouse with more severely affected models of DMD, such as the mdx/utrn+/- or 
dko mouse (Deconinck et al. 1997a,b). Although dko mice develop debilitating fibrosis at 
a young age, these animals do not tend to live past twenty weeks and thus are not 
generally used in studies examining the long-term efficacy of a therapeutic intervention.  
Similarly, although the diaphragm muscle in all three murine models develops fibrosis at 
some point, a more accurate model of DMD should reflect disease manifestation in axial 
limbs as well. Nevertheless, it would be optimal for any therapeutic drug under 
investigation to show efficacy in the diaphragm muscle since failure of this respiratory 
organ is a common cause of death in DMD patients (Bushby et al. 2009, Gilgoff et al. 
1989). Since the mdx/utrn+/- mouse develops fibrosis in both hind limb and respiratory 
skeletal muscles at a young age while not being so affected such that it dies prematurely, 
we provide further evidence here that it may be an appropriate and useful model of DMD. 
Furthermore, we report here that this increased disease severity in the mdx/utrn+/- mouse 
compared to its mdx counterpart is apparent by two months of age. The mdx/utrn+/- 
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mouse is also a suitable precursor model for scaling studies to large animal models of 
DMD such as the golden retriever model (GRMD), which exhibits signs of increased 
endomysial fibrosis as early as 15 days after birth, with severe fibrosis by 9 months of 
age (Passerini et al. 2002; Willmann 2009; Kornegay et al. 2012).  
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Chapter 3  
VEGF induces stress fiber formation in fibroblasts isolated from 
dystrophic muscle3 
  
                                                 
3
 This chapter includes content reproduced with permission from: 
Gutpell KM, Hoffman LM (2015). VEGF induces stress fiber formation in fibroblasts isolated from 
dystrophic muscle. J Cell Commun Signal, 9(4), 353–360. doi:10.1007/s12079-015-0300-z 
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3 VEGF induces stress fiber formation in fibroblasts 
isolated from dystrophic muscle 
 
3.1 Chapter Summary 
Although vascular endothelial growth factor (VEGF) has been widely studied as a 
possible therapeutic drug to treat DMD, recent work in other fibrotic disease such as 
idiopathic pulmonary fibrosis, has revealed a potential role for the growth factor in 
exacerbating fibrosis. No study to date has investigated whether VEGF elicits a fibrotic 
response in DMD, thus we sought to determine if such an effect might be exerted on 
DMD-derived fibroblasts. In this study, we isolated fibroblasts from severely affected 
diaphragm and moderately affected gastrocnemius muscles of mdx/utrn+/- mice. The 
effect of exogenous VEGF administration on expression of pro-fibrotic genes was 
assessed in vitro. The effect of VEGF on stress fiber formation was also assessed. We 
used transforming growth factor beta as a positive control in this study since it is a well-
known inducer of a fibrotic response. VEGF did not increase expression of the genes for 
type-1 collagen or connective tissue growth factor in either GM- or diaphragm-derived 
fibroblasts. Administration of the growth factor did lead to an increase in gene expression 
of alpha-smooth muscle actin, but this effect was only observed in diaphragm-derived 
fibroblasts and not GM fibroblasts. We also show that VEGF treatment leads to induction 
of alpha-smooth muscle actin-positive stress fiber formation indicative of myofibroblast 
differentiation. Stress fiber formation occurred in both GM and diaphragm fibroblasts but 
the response was more pronounced in diaphragm fibroblasts. The findings of this study 
reveal a potential role of VEGF in promoting a fibrotic response in DMD.  
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3.2 Introduction 
Angiogenic therapy has been proposed as a potential therapeutic agent for treating 
skeletal muscle ischemia inherent to Duchenne muscular dystrophy (DMD) (Shimizu-
Motohashi et al. 2014).  To this end, a number of studies have now used a potent inducer 
of angiogenesis, vascular endothelial growth factor (VEGF), as a therapeutic agent in the 
mdx mouse (Messina et al. 2007; Gregorevic et al. 2004; Beckman et al. 2013). 
Importantly, enhanced vascularization in dystrophic muscle has been shown to enhance 
the efficacy of regeneration through cell therapy (Bouchentouf et al. 2005). One aspect of 
these studies that has not been directly addressed is the effect of exogenous VEGF on 
skeletal muscle fibroblasts. Indeed, recent studies indicate that high doses of VEGF 
induce fibrosis in inflammatory and non-inflammatory stages of systemic scleroderma 
(SSc) (Maurer et al. 2014). Similarly, fibroblasts isolated from patients with idiopathic 
pulmonary fibrosis exhibit a decreased fibrotic response following treatment with a 
VEGF receptor blocker, nintedanib (Hostettler et al. 2014). The findings in the SSc study 
are particularly important because they highlight the differential effect observed with low 
levels of circulating VEGF versus high doses of VEGF typically associated with 
exogenous treatment. In contrast, studies utilizing murine models of DMD have shown 
that a loss of endogenous VEGF may have deleterious effects on regeneration. 
Additionally, results from studies that have administered VEGF to dystrophic muscle 
have suggested an anti-fibrotic role of the growth factor in this disease.  While the latter 
findings highlight the immense therapeutic potential of VEGF to treat DMD, there is 
currently a lack of studies that directly investigate the effect of exogenous VEGF 
treatment on progression of fibrosis (Miyazaki et al. 2011; Rhoads et al. 2013).  
 
Fibrosis develops in DMD patients and is largely responsible for disease fatality 
(Desguerre et al. 2009; Chen et al. 2005; Bernasconi et al. 1995). Since the mdx mouse 
model does not develop fibrosis to the same extent as is observed in patients, studying the 
effect of VEGF on the fibrotic response in this model may lead to an underestimation of 
its effect on fibrosis (Desguerre et al. 2012; Zhou et al. 2008). More recent studies have 
used a double knockout mutant that lacks both dystrophin and utrophin (dko), but this 
mouse is severely affected and does not live past 20 weeks of age (Deconinck et al. 1997; 
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Goyenvalle et al. 2010 and 2012; van Putten et al. 2012). We and others have 
demonstrated that the heterozygous mdx/utrn+/- mouse develops hind limb skeletal 
muscle fibrosis earlier in life than its mdx counterpart, but maintains a longer lifespan of 
approximately two years in laboratory conditions (Zhou et al. 2008; Gutpell et al. 2015). 
Isolation of primary fibroblasts from this mouse model thus provides a means to directly 
assess the effect of exogenous VEGF treatment on the expression of pro-fibrotic genes 
(Mezzano et al. 2007). Another important consideration for angiogenic therapy is the 
effect of treatment on different muscles affected by DMD. Indeed, all three murine 
models of DMD - mdx, mdx/utrn+/- and dko - develop fibrosis in the diaphragm muscle, 
and to a greater extent than what is observed in the hind limb musculature of any of these 
mice (Stedman et al. 1991; Huang et al. 2011). The underlying mechanism for this 
differential progression of fibrosis has not been thoroughly investigated.  Therefore, this 
study also investigated whether the effect of VEGF treatment differs in diaphragm-
derived fibroblasts versus gastrocnemius-derived fibroblasts. 
 
3.3 Materials and Methods 
3.3.1 Animal Care and Ethics Statement 
All experiments were performed at Lawson Health Research Institute at St. Joseph’s 
Health Care (SJHC) in London, Ontario.  The mdx/utrn+/- mice, originally generated by 
Dr.’s Mark Grady and Josh Sanes (Washington University, St. Louis) (Grady et al. 1997), 
were generously provided by Dr. Robert Grange (Virginia Polytechnic and State 
University) and maintained in the Animal Care Facility at SJHC. Colonies were 
maintained under controlled conditions (19–23˚C, 12 hour light/dark cycles) and allowed 
water and food ad libitum. Only 10 week-old mdx/utrn+/- mice were used in this study. 
All procedures involving animal experiments were carried out in strict accordance with 
the Canadian Council on Animal Care (CCAC) and were approved by the Animal Use 
Subcommittee at Western University. 
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3.3.2 Genotyping 
Genomic DNA from tail snips or ear notch tissue was used for genotyping. Briefly, ear 
notch tissue was lysed in a proteinase K solution at 50° C overnight. DNA was diluted 
appropriately and polymerase chain reaction was used to amplify the utrophin gene using 
Platinum Taq polymerase. Presence of the utrophin gene was detected using the 
following set of primers (Sigma): 5’-TGCAGTGTCTCCAATAAGGTATGAAC-3’, 5’-
TGCCAAGTTCTAATTCCATCAGAAGCTG -3’ (forward primers) and 5’-
CTGAGTCAAACAGCTTGGAAGCCTCC-3’ (reverse primer). 
 
3.3.3 Primary Fibroblast Isolation 
Gastrocnemius and diaphragm tissue samples were isolated from 10-week old 
mdx/utrn+/- mice. The isolation protocol was adapted from a method previously 
described by others (Mezzano et al. 2007). Briefly, mice were sacrificed via gas 
euthanasia and dissected muscles were placed in sterile phosphate-buffered saline (PBS) 
and transferred to a cell culture hood. Tissues were minced into 1-2mm3 pieces and 
placed on a gelatin-coated 10cm dish with sterile tweezers. Approximately 20-25 pieces 
were plated per dish. The tissue was then covered with primary fibroblast isolation 
medium (DMEM/F12 supplemented with 20% FBS plus penicillin and streptomycin) and 
incubated at 37°C. By day 4, fibroblasts began exiting the tissue explants. Fibroblast 
medium (DMEM/F12 supplemented with 20% FBS and penicillin and streptomycin) was 
changed every other day from this point. Cells were passaged at day 7 using 0.25% 
trypsin-EDTA. Tissue explants were removed by passing cells through a 100µm nylon 
filter. Only cells in passages 2-4 were used for experimental purposes. Fibroblast 
population was confirmed by expression of vimentin and matricellular protein CCN2 
(Appendix B). 
3.3.4 Growth Factor Supplementation 
1 x 105 fibroblasts were seeded per well onto a 12-well plate and incubated overnight. 
The next day, cells were serum-deprived in reduced-serum fibroblast medium 
(DMEM/F12 5% FBS plus penicillin and streptomycin) for 6 hours. Following serum 
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deprivation, cells were treated with 50ng/ml recombinant mouse VEGF164 (R&D 
Systems), 50ng/ml transforming growth factor–beta (TGFβ), or untreated. Growth factor 
doses were determined from previous pilot studies in our lab. TGFβ treatment served as a 
positive control for inducing a fibrotic response and the untreated fibroblasts served as a 
negative control. Cells were harvested 6 and 18 hours later for subsequent RNA 
extraction and 48 hours later for protein extraction.  
3.3.5 Quantitative Real-Time Polymerase Chain Reaction 
RNA was extracted using a QIAGEN RNeasy Plus Mini Kit. RNA concentration and 
quality was assessed using a Nanodrop Spectrophotometer ND-1000. 1-2µg of high-
quality RNA was reverse-transcribed using the High-Capacity RNA-to-cDNA Kit (Life 
Technologies). Following primer validation, Taqman Gene Expression Assays were used 
to measure Ctgf/ccn2 (Mm01192932_g1), Col1a1 (Mm00801666_g1), Acta2 
(Mm01546133_m1) and Fn1 (Mm01256744_m1) mRNA expression relative to Gapdh 
endogenous control (Mm99999915_g1) levels using the ΔΔCT method on a Real-Time 
PCR Applied Biosystems Inc. Prism 7500 under the following conditions: Initial 
denaturation at 95ºC for 5 min followed by 40 cycles of denaturation (95ºC for 15 sec), 
primer annealing (60ºC for 1 min) and transcript extension (50ºC for 2 min). All samples 
were run in triplicate. 
3.3.6 Immunohistochemistry 
Fibroblasts were processed for immunocytochemistry by fixing in 2-4% 
paraformaldehyde for 20 minutes. Fibroblasts were then washed three times with 
phosphate-buffered saline (PBS), and incubated at room temperature in blocking buffer 
(1% BSA, 10% goat serum in PBS) for 45 minutes. Fibroblasts were incubated with anti-
α-SMA (Abcam, 1:100) primary antibody. Following thorough washing with PBS, 
Alexafluor 488-IgG (Life Technologies, 1:1000) secondary antibody was used to 
visualize the primary antibody, and ProLong Gold anti-fade with DAPI (Life 
Technologies) was added to visualize the nuclei and to mount the coverslips onto glass 
slides. Fluorescent images were acquired at a twenty times magnification on a Nikon 
Eclipse microscope. 
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3.3.7 Western Blot 
Cells were collected in Phosphosafe lysis buffer containing a protease inhibitor cocktail 
and lysed via sonication. Cell culture supernatants were collected and lyophilized for 210 
minutes at 45°C and re-suspended in PBS. Protein was quantified using the bicinchoninic 
acid assay (Pierce). 50μg of protein was heat denatured and loaded onto a TGX stain-free 
SDS gel. Protein was transferred onto a PVDF low fluorescence membrane using the 
Transblot Turbo machine (Bio-Rad) and total protein was visualized on the Bio-Rad Gel 
Doc system. Membranes were blocked with 5% bovine serum albumin in tris-buffered 
saline containing 0.05% tween 20 for 1 hour. Blots were then incubated with primary 
anti-fibronectin antibody (1:1000, Abcam) at 4°C overnight.  Following thorough 
washing in TBS-T, blots were incubated with anti-rabbit HRP secondary antibody 
(1:5000) for 1 hour. Bands were visualized via chemiluminescence using ImageLab 
software (Bio-Rad) and normalized to total protein signal from the stain-free blots 
(Taylor et al. 2013). Bands from cell culture supernatants are shown for qualitative 
purposes only since normalization to total protein was not possible given the signal 
saturation from the serum.  
3.3.8 Statistical Analysis 
Gene expression data was analyzed using a two-way analysis of variance (ANOVA) to 
determine simple main effects of treatment and time point followed by individual one-
way ANOVA to assess differences within the 6- and 18-hour time points. Differences 
between groups were determined using Tukey’s post-hoc test. A p-value less than 0.05 
was considered significant (n=6 and n=4 for gene expression and protein experiments, 
respectively). 
 
3.4 Results 
3.4.1 Effect of VEGF on Fibrotic Gene Expression 
Expression of multiple genes involved in dysregulated tissue repair was measured to 
investigate whether VEGF induces a fibrotic response in fibroblasts derived from 
dystrophic muscle. Specifically, changes in mRNA levels of Ctgf/ccn2, Col1a1, Fn1, and 
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Acta2, were assessed in diaphragm and GM-derived fibroblasts. TGFβ increased 
expression of Ctgf/ccn2 in both GM- and diaphragm-derived fibroblasts. Six hours 
following administration, a 4.6- and 14.2-fold increase in expression of the gene was 
measured in GM (p<0.0001) and diaphragm fibroblasts (p=0.0002), respectively (Figure 
3.1). This level of Ctgf/ccn2 expression was significantly higher than expression in either 
control fibroblasts or VEGF-treated fibroblasts. There was no measureable increase in 
Ctgf/ccn2 transcript level following VEGF treatment in either diaphragm or GM 
fibroblasts. The gene that encodes the pro-alpha(I) chain of type-1 collagen, was assessed 
to represent changes in collagen expression (Figure 3.2). TGFβ led to significantly higher 
expression of Col1a1 in GM fibroblasts compared to either control or VEGF-treated GM 
fibroblasts. In diaphragm fibroblasts Col1a1 expression was higher in TGFβ-treated 
fibroblasts compared to controls, but not higher than in VEGF-treated fibroblasts. 
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Figure 3.1: VEGF does not increase expression of Ccn2/ctgf in fibroblasts derived 
from GM or diaphragm muscle of mdx/utrn+/- mice.  
Fibroblasts isolated from gastrocnemius (top) or diaphragm muscles (bottom) of 
mdx/utrn+/- mice were treated with VEGF164 for 6 or 18 hours. Treatment with TGFβ, a 
known-inducer of pro-fibrotic gene expression, was used as a positive control. Ctgf/ccn2 
expression levels were measured relative to Gapdh (n=6). * and † denote significant 
difference between groups within the 6 and 18 hour time points, respectively. **p<0.01, 
***p<0.001, ****p<0.0001 +SD. 
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Figure 3.2: VEGF does not increase expression of Col1a1 in fibroblasts derived from 
GM or diaphragm muscle of mdx/utrn+/- mice.  
Fibroblasts isolated from gastrocnemius (top) or diaphragm muscles (bottom) of 
mdx/utrn+/- mice were treated with VEGF164 for 6 or 18 hours and expression of 
Col1a1 was assessed via qPCR.  Treatment with TGFβ, a known-inducer of pro-fibrotic 
gene expression, was used as a positive control. Col1a1 expression levels were measured 
relative to Gapdh (n=6), * and † denote significant difference between groups within the 
6 and 18 hour time points, respectively **p<0.01, ***p<0.001, +SD 
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3.4.2 Effect of VEGF on fibronectin expression 
 
To determine if VEGF stimulates expression of genes that encode the extracellular matrix 
protein fibronectin, we assessed changes in mRNA expression of Fn1. Neither TGFβ nor 
VEGF altered expression of Fn1 by any time points assessed in this study (Figure 3.3). 
Conversely, Western blot analysis of fibronectin protein (FN) confirmed that VEGF, but 
not TGFβ, increased expression of the protein by 1.9-fold in diaphragm fibroblasts 
(p=0.029) and by 1.5-fold in GM fibroblasts (p=0.001). Similar qualitative trends were 
observed in FN levels in the supernatant (Figure 3.4).  
3.4.3 Changes in αSMA Expression Following VEGF Treatment 
 
Acta2 expression significantly increased in GM-derived fibroblasts 1.8-fold following 
TGFβ treatment, but not following VEGF treatment (Figure 3.5). Acta2 expression in 
diaphragm-derived fibroblasts, on the other hand, responded to both TGFβ treatment as 
well as VEGF treatment. TGFβ induced a 1.5-fold increase compared to control cells as 
early as 6 hours after administration of the growth factor. By 18 hours, Acta2 expression 
was 1.9- and 1.5-fold higher in fibroblasts treated with TGFβ and VEGF, respectively 
(p<0.0001). Immunocytochemical analysis revealed minimal αSMA expression in both 
GM and diaphragm fibroblasts. While all αSMA protein expressed in untreated GM-
fibroblasts was located in the cytoplasm (Figure 3.6), some untreated αSMA-positive 
diaphragm fibroblasts expressed the protein within stress fibers (Figure 3.7).  TGFβ 
induced a robust response in diaphragm fibroblasts resulting in high levels of αSMA 
expression. Myofibroblast differentiation in these cells was evident by stress fiber 
formation. A similar, but less striking, response was observed in diaphragm fibroblasts 
treated with VEGF, as a large portion of these cells also underwent stress fiber formation. 
GM-derived fibroblasts appeared to respond to both TGFβ and VEGF, although the 
response was more subdued compared to the one observed in diaphragm fibroblasts. 
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Figure 3.3: Fn1 expression in is not altered by VEGF or TGFβ in fibroblasts 
isolated from either GM or diaphragm muscles of  mdx/utrn+/- mice.  
Fibroblasts isolated from gastrocnemius (top) or diaphragm muscles (bottom) of 
mdx/utrn+/- mice were treated with VEGF164 for 6 or 18 hours. Treatment with TGFβ, a 
known-inducer of pro-fibrotic gene expression, was used as a positive control. Fn1 
expression levels were measured relative to Gapdh (n=6), *significant difference between 
treatment groups within the 6 hour time point, †significant difference between groups 
within the 18 hour time point. 
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Diaphragm#
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Figure 3.4: FN levels are increased following treatment of diaphragm and GM 
fibroblasts with VEGF.  
Western blot analysis (A) reveals an increased level of intracellular FN and extracellular 
FN located in the cell culture supernatant following 48 hours in the presence of VEGF164. 
FN levels from cell lysates of diaphragm (B) and GM (C) fibroblasts were measured 
relative to total protein (n=4, *p<0.05, **p<0.01). 
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Figure 3.5: VEGF increases Acta2 expression in diaphragm, but not in GM 
fibroblasts derived from mdx/utrn+/- mice.  
Fibroblasts isolated from gastrocnemius (top) or diaphragm muscles (bottom) of 
mdx/utrn+/- mice were treated with VEGF164 for 6 or 18 hours. Treatment with TGFβ, a 
known-inducer of pro-fibrotic gene expression, was used as a positive control. Acta2 
expression levels were measured relative to Gapdh (n=6), *significant difference between 
treatment groups within the 6 hour time point, †significant difference between groups 
within the 18 hour time point. *p<0.05, **p<0.01, ±SD. 
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Figure 3.6: VEGF induces stress fiber formation in GM fibroblasts indicative of 
myofibroblast differentiation.  
GM fibroblasts were treated with VEGF164 for 48 hours. Treatment with TGFβ, a known-
inducer of pro-fibrotic protein expression, was used as a positive control. Alpha-smooth 
muscle actin (αSMA), a marker of myofibroblasts, is shown in green. DAPI (blue) was 
used as a counterstain (scale bar= 50µm). 
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Figure 3.7: VEGF induces stress fiber formation in diaphragm fibroblasts indicative 
of myofibroblast differentiation.  
Diaphragm fibroblasts were treated with VEGF164 for 48 hours. Treatment with TGFβ, a 
known-inducer of pro-fibrotic protein expression, was used as a positive control. Alpha-
smooth muscle actin (αSMA), a marker of myofibroblasts, is shown in green. DAPI 
(blue) was used as a counterstain (scale bar= 50µm). Although some untreated control 
fibroblasts are αSMA-positive, treatment with either TGFβ or VEGF led to greater 
expression of the protein in stress fibers.  
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3.5 Discussion 
Therapeutic approaches to slow or attenuate the degenerative effects of DMD include 
attempts to restore dystrophin, the cytoskeletal protein that is missing or aberrant in DMD 
patients (Pessina et al. 2014). Gene and stem cell therapies are but two approaches 
currently under intense investigation to serve this purpose, but both of these are limited 
by the hostile microenvironment where regenerative therapy needs to occur. Skeletal 
muscle in both patients and animal models of DMD is poorly vascularized, leading to 
studies exploring the use of pro-angiogenic therapies to enhance the ischemic 
microenvironment (Arsic et al. 2004; Borselli et al. 2010). VEGF is a particularly 
attractive candidate for such a therapy since it is a well-known, potent inducer of 
angiogenesis. Although the literature currently suggests that VEGF enhances cell 
engraftment in the mdx mouse (Messina et al. 2007; Deasy et al. 2009), it remains to be 
determined whether VEGF induces a fibrotic response in DMD. In fact, a reduction in 
fibrosis following delivery of muscle-derived stem cells overexpressing VEGF has been 
shown in the mdx GM muscle (Deasy et al. 2009). The main motivation for this study 
was the findings from recent studies that examined the effect of VEGF in other fibrotic 
diseases such as SSc and idiopathic pulmonary fibrosis, whereby elevated levels of 
VEGF increased markers of fibrosis. In contrast, inhibition of VEGF was shown to have 
an anti-fibrotic effect (Maurer et al. 2014; Hostettler et al. 2014). These studies highlight 
the need to assess angiogenic therapy for the treatment of DMD in an animal model that 
develops significant fibrosis. Since the mdx mouse does not develop fibrosis as severely 
and early as DMD patients (Konieczny et al. 2013), our study focused on investigating 
the effect of VEGF on fibroblasts derived from a more fibrotic mouse model of DMD, 
the mdx/utrn+/- mouse (Zhou et al. 2008). Furthermore, since most studies to date have 
focused on the effect of VEGF on the hind limb muscles, our second objective was to 
determine whether there is a differential response to VEGF in diaphragm and 
gastrocnemius fibroblasts. To this end, gene expression analyses in the present study have 
indicated that VEGF treatment may alter expression of some genes involved in the 
fibrotic response, specifically Acta2, the gene that encodes αSMA. Expression of the 
genes that encode CTGF/CCN2 and collagen were not altered by VEGF, however these 
findings were inconclusive since we did not further investigate the levels of these two 
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proteins following treatment. Visualization of αSMA expression in VEGF-treated cells 
suggests a role for this growth factor in promoting differentiation of these fibroblasts, 
particularly ones derived from the diaphragm, into myofibroblasts.  
 
Although Fn1 levels were not affected by either treatment, protein levels of FN increased 
in the presence of VEGF, but not TGFβ. It is perhaps not surprising that exogenous TGFβ 
did not stimulate increased FN levels compared to the control treatment since all cells in 
this study were derived from mdx/utrn+/- mice. Previous work has demonstrated that 
conditioned media from mdx fibroblasts stimulates a fibrotic response, including 
increased FN, in wild-type fibroblasts (Mezzano et al. 2007). Given these findings, it may 
be that untreated fibroblasts in the present study also secreted pro-fibrotic factors into the 
culture medium, leading to an increase in FN even in the absence of exogenous TGFβ. 
Thus, the finding that exogenous VEGF treatment increased FN levels in our study is 
particularly intriguing. Since VEGF treatment resulted in increased FN protein but did 
not alter mRNA expression, it appears that VEGF may act translationally or post-
translationally to enhance FN expression in mdx/utrn+/- fibroblast cultures.  The fact that 
VEGF treatment led to increased FN both in cell lysates and cell culture supernatant 
warrants further investigation. This finding is consistent with work in other animal 
models of disease such as preclinical diabetic retinopathy whereby exogenous VEGF 
injection to a rat retina induced expression of FN as well as other fibrotic markers 
(Kuiper et al. 2007). That VEGF only affected protein, but not mRNA, levels in the 
present study also warrants further analysis. Since only two time points were assessed 
here, looking at FN mRNA expression over a time course may yield different results than 
those attained in this study.  Interestingly, work over the past decade has revealed binding 
sites for VEGF on full length fibronectin and these studies have suggested that, in this 
case, the binding of these two proteins in the ECM act to increase the biological activity 
of VEGF (Wijelath et al. 2002, 2004; Goerges and Nugent 2004; Vempati et al. 2014). 
Further, it is well known that loss of FN negatively impacts vasculogenesis and 
angiogenesis due, in part, to the decrease in VEGF activity (Astrof and Hynes 2009). 
Although previous work highlights an important interaction between FN and VEGF, our 
results are the first to show a potential effect of VEGF on FN expression. As such, the 
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role of this interaction in the context of angiogenesis in dystrophic muscle also warrants 
further detailed investigation. 
 
Given that diaphragm and GM muscles in mdx/utrn+/- mice display different abilities to 
develop fibrosis, we investigated whether fibroblasts from these different muscles also 
respond differently to VEGF treatment. Although the two cell types showed similar gene 
expression profiles following treatment, there were a few key differences observed here. 
First, untreated diaphragm fibroblasts appear to be more myofibroblast-like than GM 
fibroblasts, as evidenced by the presence of αSMA stress fibers, which were rare in the 
GM fibroblast cultures. Further, TGFβ stimulated a more drastic response in diaphragm 
fibroblasts compared to GM fibroblasts, evidenced by higher αSMA expressed and more 
prominent stress fiber formation. A similar trend was observed following VEGF 
treatment, although not to the same extent as observed following TGFβ administration. 
These findings suggest that fibroblasts from different muscles may respond in a unique 
way to various growth factors. As such, further work will be needed to determine whether 
diaphragm-derived fibroblasts indeed respond differently to VEGF treatment than do 
hind limb muscles. Since the pathology progression is more rapid in the diaphragm than 
hind limb muscles, considering the effect of treatment on both of these muscles will be 
crucial for future work.  
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4 Vascular-targeted therapy attenuates ischemia and 
fibrosis in DMD mice 
4.1 Chapter Summary 
A number of limitations currently surround the use of vascular-targeted therapy to treat 
DMD. The previous chapters describe the use of a murine model that develops more 
fibrosis than the mdx mouse. Results from chapter 2 indicate the mdx/utrn+/- mouse, a 
model that lacks dystrophin and is heterozygous for utrophin, exhibits more collagen 
deposition at an early age compared to its mdx counterpart. Using the mdx/utrn+/- mouse, 
chapter 3 demonstrated a potential role of VEGF in eliciting a fibrotic response in vitro in 
fibroblasts derived from the diaphragm and, to a lesser extent, the gastrocnemius muscles 
from this murine model. It is not well known whether VEGF alone induces functional 
changes in perfusion in a relevant murine model of DMD or if another factor, 
angiopoietin-1 (ANG1), is also necessary. Further, whether VEGF exerts a pro-fibrotic 
effect has not been confirmed in vivo. Using dynamic contrast-enhanced computed 
tomography (DCE-CT) to measure perfusion, we show that functional perfusion 
decreases over a two week period and that blood flow and blood volume are unaffected 
by localized delivery of VEGF alone compared to sham-injected controls. In contrast, 
mice treated with a combination of VEGF and ANG1, exhibit reduced progression of 
ischemia over the treatment period, evidenced by a lesser reduction in blood volume 
compared to either the sham- or VEGF-treated mice. These vascular differences are 
validated histologically by increased vessel maturation in hind limb muscles that received 
the combination treatment. There is also histological evidence that VEGF and ANG1 
treatment resulted in reduced infiltration of leukocytes into the muscle tissue and reduced 
deposition of collagen in the endomysium.  
  
86 
 
4.2 Introduction 
Vascular-targeted therapy to treat Duchenne muscular dystrophy (DMD) has been 
investigated since the early 2000’s (Shimizu-Motohashi et al 2014). The proposed 
mechanisms by which angiogenic therapy may alleviate the pathophysiology associated 
with DMD are numerous. Previous work has provided evidence of compromised 
vasculature in the disease, including impaired angiogenesis (Palladino et al 2013) and 
decreased vascular density in the mdx mouse, the most widely used murine model of 
DMD (Loufrani et al 2004), as well as in the gold-retriever model of (Nguyen et al 2005). 
As such, many groups have attempted to increase vascular density in dystrophic muscle 
by treating it with vascular endothelial growth factor (VEGF), a well-known and potent 
inducer of angiogenesis (Messina et al. 2007; Gregorevic et al. 2004; Beckman et al. 
2013). Histological markers of endothelial cells, cells that make up the luminal wall of 
vessels, demonstrate increased vascular density following VEGF treatment. Other studies 
have also shown that VEGF levels are decreased in some muscle groups in mdx mice as 
well as in patients (Abdel-Salam et al 2009). These findings are somewhat inconclusive, 
though, as others have shown that VEGF levels are increased in dystrophic muscle tissue. 
This discrepancy is likely due to a temporally dependent alteration in VEGF expression 
at various stages of the disease. Interestingly, hypoxia-inducible factor-1 alpha (HIF1-α) 
is increased in DMD patients (Abdel-Salam et al 2010) and others have shown that 
increases in HIF1-α in the mdx mouse brain correspond to elevated levels of VEGF (Nico 
et al 2007).  
Although promising results have been shown regarding the use of VEGF to 
alleviate ischemia, there are a number of questions that remain unanswered. First, it has 
been widely proposed that VEGF, while inducing angiogenesis, creates only immature 
and “leaky” vessels that do not confer significant functional benefit to the muscle 
(Gavard et al 2008). Although histological analyses have revealed an increase in vascular 
density following VEGF treatment, whether these newly formed vessels are functional 
has not been rigorously investigated. Groups have therefore begun to use VEGF in 
combination with other factors, particularly angiopoietin-1 (ANG1), to induce vascular 
maturation (Chae et al 2000; Shyu et al 2003; Yamauchi, et al 2003 Chen et al 2007).  
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Binding of ANG1 to the Tie2 receptor on endothelial cells activates the receptor’s 
tyrosine kinase activity, producing a cellular response that results in vessel survival and 
stabilization (Fukuhara et al 2010). Receptor activation increases phosphatidylinositol 3-
kinase (PI3K) activity, leading to stimulation of AKT, a cell survival signaling molecule 
that inhibits transcription factors essential in vascular destabilization (Daly et al., 2004). 
Activation of the PI3K pathway also increases expression of survivin, an inhibitor of 
apoptosis in endothelial cells (Papapetropoulos et al., 2000). Upon Tie2 activation, 
vascular-endothelial cadherin increases adhesion between endothelial cells, lending to an 
increase in overall vessel stability (Gamble et al., 2000; Gavard et al 2008). Importantly, 
ANG1 recruits vascular smooth muscle cells by signaling through endothelial cells 
(Iivanainen et all 2003, Kobayashi et al 2006). This vascular smooth muscle lining 
ultimately confers functional maturity to newly formed vasculature (Brudno et al 2013).  
Given the role of VEGF and ANG1 in angiogenesis, various groups have 
attempted to exploit their function as a vascular-targeted approach to treating ischemia in 
DMD (Mofarrahi et al 2015).  Indeed, VEGF administration has been shown to increase 
endogenous repair and enhance the efficacy of transplanted cell populations. Still, 
questions remain regarding the reality of using these factors to treat DMD. Importantly, 
very little data exists describing the functional efficacy these factors exert in a 
longitudinal manner in DMD models. Position emission tomography demonstrates that 
blood flow is not affected by VEGF treatment alone in the rat skeletal muscle, but is 
significantly increased when VEGF is combined with ANG1 (Zaccigna et al 2007). Thus, 
the objective of the present study is to non-invasively assess the effect of VEGF 
treatment alone or in combination with ANG1 on functional angiogenesis in dystrophic 
murine hind limb skeletal muscle. Our group has previously reported the use of dynamic 
contrast-enhanced computed tomography (DCE-CT) to monitor disease progression in 
murine models of DMD (Ahmed et al 2011), but no study to date has attempted to assess 
therapeutic intervention in preclinical studies using this imaging modality. Further, we 
utilize the mdx/utrn+/- mouse, a model that lacks dystrophin and is heterozygous for 
utrophin, a dystrophin analogue. Previous studies have suggested the heterozygous mouse 
as a superior model for DMD research since this mouse develops fibrosis to a greater 
extent compared to the dystrophin-null mdx mouse (Zhou et al 2008). Using the 
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mdx/utrn+/- mouse, which is more prone to fibrosis, is of particular importance given 
recent findings showing a potential role of VEGF in exacerbating disease severity in 
other fibrotic diseases such as scleroderma and idiopathic pulmonary fibrosis (Maurer et 
al. 2014 & Hostettler et al. 2014). Additionally, long-term overexpression of VEGF 
promotes fibrosis in skeletal muscle in the ischemic hind limb rabbit model (Karvinen et 
al 2011). 
4.3 Materials and Methods 
4.3.1 Animal Care and Ethics Statement 
Experiments were performed at The Lawson Health Research Institute at St. Joseph’s 
Health Care (SJHC) in London, Ontario. Heterozygous mdx/utrn+/- mice, originally 
generated by Dr.’s Mark Grady and Josh Sanes (Washington University, St. Louis) [12], 
were generously provided to us by Dr. Robert Grange (Virginia Polytechnic and State 
University) and maintained in the Animal Care Facility at SJHC. Colonies were 
maintained under controlled conditions (19-23˚C, 12 hour light/dark cycles) and allowed 
water and food ad libitum. Nine to ten week-old male mice were used in this study. All 
procedures involving animal experiments were carried out in strict accordance with the 
Canadian Council on Animal Care (CCAC) and were approved by the Animal Use 
Subcommittee at Western University. 
4.3.2 Genotyping 
Genomic DNA from tail snips or ear notch tissue was used for genotyping. Briefly, ear 
notch tissue was lysed in a proteinase K solution at 50° C overnight. DNA was diluted 
appropriately and polymerase chain reaction was used to amplify the utrophin gene using 
Platinum Taq polymerase. Presence of the utrophin gene was detected using the 
following set of primers (Sigma): 5’-TGCAGTGTCTCCAATAAGGTATGAAC-3’, 5’-
TGCCAAGTTCTAATTCCATCAGAAGCTG -3’ (forward primers) and 5’-
CTGAGTCAAACAGCTTGGAAGCCTCC-3’ (reverse primer). 
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4.3.3 Enzyme-linked immunosorbent assays  
To determine endogenous levels of VEGF and ANG1, we used a Quantikine Mouse 
VEGF kit (R&D Systems) and a Mouse ANG1 ELISA kit (Lifespan Biosciences). 10 
week-old mdx/utrn+/- mice (n=6) and C57Bl10 (n= 6) were euthanized. Dissected tissue 
was placed in ice cold PBS, homogenized and stored overnight at -20 ° C to ensure 
complete lysis of homogenates. Samples were then centrifuged at 5000xg for 5 minutes 
and only the supernatant assayed. Total protein was quantified using the BCA Assay 
(Pierce) prior to ELISA assay. All samples were run in duplicate and absorbance was 
measured at 450nm.  
4.3.4 Local Delivery of Growth Factors 
Affi-Gel Blue Beads (BioRad) were air-dried in a cell culture hood under sterile 
conditions overnight. The next day, beads were resuspended in 10μl of: sterile phosphate-
buffered saline (PBS), 0.5μg recombinant mouse VEGF, 5μg recombinant human ANG1, 
or a combination of VEGF and ANG1. Beads were incubated in the growth factors 
overnight. The next day, beads were centrifuged for 5 minutes at 12,000rpm, the 
supernatant was removed and the beads were re-suspended in 10μl sterile PBS. Hind limb 
hair was gently plucked and the exposed skin was wiped with isopropyl alcohol to ensure 
sterility. The beads were implanted intramuscularly into the posterior compartment of the 
hind limb (lateral head of the gastrocnemius muscle) as follows: mice in the “sham” 
group received PBS-soaked beads in both hind limbs, “VEGF” mice received PBS-
soaked beads in the right hind limb and VEGF-coated beads in the left, and the 
“VEGF+ANG1” group received VEGF-coated beads in the right hind limb and 
VEGF+ANG1-coated beads in the left. Injections took place before the anatomical axial 
CT scan while the mouse was anesthetized. 
4.3.5 Dynamic Contrast-Enhanced Computed Tomography 
Mice were scanned at baseline and 2 weeks post-injection (time point based on pilot 
studies previously conducted in our lab, Appendices C,D). During each imaging session, 
anesthesia was induced with 3% isofluorane and maintained with a 1.5% oxygen-
balanced isofluorane mixture, delivered at a constant rate of 1L/min. DCE-CT protocol 
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was adapted from a previous study (Ahmed et al. 2011). Briefly, following an anatomical 
axial scan, each mouse received 200 μL of Conray 43 contrast agent (diluted 1:2 with 
saline) at an injection rate of 2.0 ml/min with an infusion pump (New Era Pump Systems 
Inc) via tail vein catheter. CT Perfusion software (GE Healthcare) was used to quantify 
blood flow (BF) and blood volume (BV) based on functional maps from the acquired 
series of CT images (Cenic A, et al., 1999). Perfusion data acquired for each mouse was 
normalized to baseline values to minimize biological variability between animals, thus 
allowing us to assess longitudinal changes between groups. Regions of interest were 
drawn around the whole cross-sectional slice of the hind limb, excluding the tibia and 
fibula, and three slices covering the leg were included in each calculation (Appendix E). 
4.3.6 Tissue Preparation  
At the end of the imaging study, mice were sacrificed via gas euthanasia followed by 
cervical dislocation. Gastrocnemius and diaphragm muscles were dissected, immediately 
fixed in formalin, and embedded in paraffin. Extreme care was taken to ensure muscles 
were embedded in the same orientation across each muscle group. Tissue blocks were 
sectioned at 5um thickness and dried in an oven at 37˚C overnight. To achieve 
representative sections from the whole muscle tissue, serial sections were taken every 20 
or 5 slices for the GM and diaphragm muscles, respectively. Tissue sections were then 
deparaffinised and rehydrated in a series of xylene and ethanol washes to prepare them 
for subsequent Masson’s Trichrome staining for collagen content (performed at the 
Pathology Department at University Hospital, London, ON), or haematoxylin and eosin 
staining to visualize inflammation. Serial sections were used for the two staining methods 
to ensure that analysis of both collagen content and inflammation referred to the same 
samples. Following the staining step, slides were dehydrated, washed in xylene and 
mounted with Permount mounting medium.   
4.3.7 Immunohistochemistry 
Tissue sections were processed for immunocytochemistry by deparaffinising and 
rehydrating sections followed by heat-mediated antigen retrieval in a citrate buffer for 20 
minutes.  Slides were then cooled slowly to room temperature and incubated in blocking 
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buffer (1% BSA, 10% goat serum in PBS) for one hour. Sections were incubated with 
anti-αSMA (Abcam, 1:100) or anti-CD45 (Abcam, 1:50) primary antibodies at 4°C 
overnight. Following thorough washing with PBS, Alexa Fluor IgG (Life Technologies, 
1:1000) secondary antibodies were used to visualize the primary antibodies, and ProLong 
Gold anti-fade with DAPI (Life Technologies) was added to visualize the nuclei and to 
mount the coverslips onto glass slides. Fluorescent images were acquired on a Nikon 
Eclipse microscope. 
4.3.8 Microscopy and Image Analysis 
For Masson’s Trichrome sections, colour histological images were acquired on a Zeiss 
Axioscope microscope under 10x objective using Northern Eclipse software. Non-
overlapping fields of view of the entire tissue were taken for each section. Collagen 
content was assessed across the entire tissue slice and automatically quantified using an 
in-house colour thresholding algorithm written in MATLAB 2015b (Mathworks, Natick, 
MA, USA) designed to separate red and blue image components as previously described 
(Gutpell et al. 2015). The percentage of each slide area positive for collagen presence was 
calculated, and automatic thresholds were manually verified with labeled colour overlays 
on the original histology images to ensure that collagen presence was accurately 
identified.  
For αSMA and CD45 sections, grey scale fluorescence images were acquired on a Nikon 
Eclipse Microscope using NIS Elements Microscope Image Software. Non-overlapping 
fields of view of the entire tissue were taken for each section. A semi-automatic grey 
scale thresholding algorithm was implemented in MATLAB 2015a to quantify the area of 
each slide positive for αSMA or CD45 while mitigating variations due to image exposure 
and auto-fluorescence; referred to as “background” intensity variations. The three major 
steps of the algorithm are 1) background intensity estimation, 2) stain identification, and 
3) stain area calculation. These steps are briefly described as follows. 1) The intensity 
gradient magnitude of each slide was calculated, and contiguous regions with a gradient 
magnitude less than a constant threshold were assigned as background. This background 
threshold was empirically selected as 40 intensity units, or roughly 8% of the maximum 
signal intensity gradient observed across slides. 2) All closed non-background regions 
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with maximum signal intensity greater than a stain threshold were assigned positive for 
stain presence. The stain threshold was manually selected as either 4× or 5× times the 
mean background signal intensity of each slide. 3) Within each closed non-background 
region considered positive for stain presence, the final stained area was determined by 
applying a threshold of 25% of the maximum intensity in that region. The percentage of 
total area positive for stain was calculated for each slide. Again, automatic thresholds 
were manually verified using labeled colour overlays on the original images, and any 
features incorrectly identified as positive for stain were manually edited. 
4.3.9 Western Blot 
Tissue was collected in Phosphosafe lysis buffer (EMD Millipore) containing a protease 
inhibitor cocktail (EMD Millipore) and homogenized. Protein was quantified using the 
bicinchoninic acid assay (Pierce). 25 μg of protein was heat denatured and loaded onto a 
TGX stain-free SDS gel. Protein was transferred onto a PVDF low fluorescence 
membrane using the Transblot Turbo machine (Bio-Rad) and total protein was visualized 
on the Bio-Rad Gel Doc system. Membranes were blocked with 5% bovine serum 
albumin in Tris-buffered saline containing 0.05% Tween 20 for 1 hour. Blots were then 
incubated with primary αSMA (1:1000, Abcam) or anti-CD45 (1:500, Abcam) primary 
antibodies at 4°C overnight.  Following thorough washing in TBS-T, blots were 
incubated with anti-rabbit or anti-mouse horseradish peroxidase secondary antibodies 
(1:5000) for 1 hour. Bands were visualized via chemiluminescence using ImageLab 
software (Bio-Rad) and normalized to total protein signal from the stain-free blots 
(Taylor et al. 2013). 
4.3.10 Statistical Analysis 
Data was analyzed using Student’s t-test for ELISA results and an analysis of variance 
(ANOVA) for the perfusion and histology results. Differences between groups were 
determined using Tukey’s post-hoc test. A p-value less than 0.05 was considered 
significant. Replicate values for each experiment are presented with the results.  
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4.4 Results 
4.4.1 Endogenous levels of both VEGF and ANG1 are significantly 
reduced in severely fibrotic diaphragm tissue, but not weakly 
affected GM tissue of the mdx/utrn+/- mouse 
Endogenous expression of VEGF and ANG1 was measured in the diaphragm and GM 
muscles at 9-10 weeks of age (Figure 4.1). The level of VEGF in GM muscle of 
mdx/utrn+/- mice (19.6pg/ml) was similar to that measured in wild-type mice 
(19.3pg/ml, p=0.93). However, compared to healthy diaphragm muscle (63.0pg/ml), the 
concentration of VEGF in dystrophic diaphragm muscle (39.2pg/ml) was significantly 
reduced (p=0.0049). A similar trend was observed for the endogenous concentration of 
ANG1 in healthy versus dystrophic diaphragm and GM muscles. Specifically, ANG1 
expression in healthy and dystrophic GM muscles was 85.3 and 54.1 pg/ml, respectively, 
but these values were not determined to be significantly different from one another 
(p=0.09). In contrast, a marked reduction of ANG1 expression was measured in the 
diaphragm of dystrophic mice relative to wild-type controls (148.3 and 365.6 pg/ml, 
respectively; p<0.0001). 
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Figure 4.1: VEGF and ANG1 are decreased in dystrophic diaphragm and murine 
muscles.   
ELISA analysis of VEGF and ANG1 in 9 to 10 week-old mdx/utrn+/- diaphragm and 
GM muscles compared to healthy wild type controls. A. VEGF was lower in mdx/utrn+/- 
diaphragm muscles compared to healthy wild-type controls. VEGF expression was not 
significantly different between dystrophic and healthy GM muscles. B. ANG1 was lower 
in mdx/utrn+/- diaphragm muscles compared to healthy wild-type controls. ANG1 
expression was not significantly different between dystrophic and healthy GM muscles.   
n = 6 per group, *P < 0.05, by Student’s t-test. Error bars represent SD. 
 
A 
B 
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4.4.2 Effect of VEGF and ANG1 on perfusion 
Blood flow (BF) and blood volume (BV) were assessed as parameters of perfusion in this 
study. There was no significant difference measured between the two hind limbs, 
regardless of treatment. BF and BV are therefore presented as fold change averages 
between the two limbs after 16 days of growth factor treatment (Figure 4.2).  Absolute 
values for BF and BV indicate that measurements were not significantly different among 
mice in different treatment groups at baseline (Table 4.1). Baseline values also indicate 
the degree of variability between mice. BF decreased in all mice, regardless of treatment, 
over the course of the study (Figure 4.3). There was no significant difference in BF fold 
change between sham-injected (0.417±0.26), VEGF-treated (0.408±0.17), and 
VEGF+ANG1-treated mice (0.979±0.64; p= 0.0614). BV also decreased over the two-
week period, but the change was less marked in mice that received the combination 
treatment of VEGF+ANG1 (0.847±0.40) compared to either the sham-injected control 
(0.284±0.12) or VEGF-treated groups (0.398±0.16; p= 0.0109). No significant difference 
in BV fold change was measured between the sham-injected and VEGF-treated mice 
(Figure 4.4). 
4.4.3 VEGF and ANG1 increase vessel maturation in 
gastrocnemius muscle of mdx/utrn+/- mice 
Western blot analysis was employed to assess total alpha-smooth muscle actin (αSMA) in 
GM tissue homogenates following the two-week treatment period (Figure 4.5). Total 
αSMA expression was increased in GM muscles from VEGF+ANG1 treated mice 
compared to controls. Since αSMA identifies both blood vessels as well as 
myofibroblasts, we further employed IHC analysis to determine αSMA expression only 
in vessels (Appendix F). While no significant differences were measured between the 
sham-injected (0.18% ±0.033) and the VEGF-treated mice (0.23% ±0.066), we did 
measure a significant increase in αSMA-positive vessels in hind limb muscles treated 
with both VEGF and ANG1 (0.36% ±0.054) relative to either sham or VEGF-treated 
mice (p<0.0001). Many newly formed αSMA-positive vessels were detected at the 
injection area in VEGF+ANG1-treated hind limbs. Very few mature vessels were 
observed at the injection site of VEGF-treated hind limbs.   
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Figure 4.2: Perfusion measured at endpoint is not significantly different between 
hind limbs, regardless of treatment. 
(A) Schematic representation of treatment groups. “Sham” group mice received PBS-
soaked beads in both hind limbs. “VEGF” mice received PBS-soaked beads in the right 
hind limb and VEGF-coated beads in the contralateral limb. VEGF+ANG1 mice received 
VEGF-coated beads in the right hind limb and VEGF+ANG1-coated beads in the 
contralateral limb. (B) Blood flow and blood volume did not differ between hind limbs, 
allowing for perfusion measurements to be assessed based on the averaged BF and BV 
following treatment. n=5 for sham, n=6 for VEGF, n=5 for VEGF+ANG1, P < 0.05, by 
Wilcoxon signed-rank test.  
Sham%
VEGF%
VEGF+ANG1%
B%
A%
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Table 4.1: Mean absolute values (mean ± SD) of blood flow (BF) and blood volume 
(BV) for each experimental group at baseline.  
P-values to the right of each mean column indicate that no significant difference existed 
between treatment groups at baseline. n=5 for sham, n=6 for VEGF, n=5 for 
VEGF+ANG1, P < 0.05, by one-way ANOVA. 
 
Treatment Absolute BF 
±SD 
BF 
p-value 
Absolute BV 
±SD 
BV 
p-value 
Sham 59.8 ± 25.1 
0.1008 
7.1 ± 3.1 
0.1007 VEGF 51.6 ± 8.3 4.7 ± 2.2 
VEGF+ANG1 36.8 ± 9.8 3.8 ± 1.6 
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Figure 4.3: Low dose delivery of pro-angiogenic growth factors does not affect blood 
flow 18 days post-treatment in mdx/utrn+/- hind limb skeletal muscle.   
A. Representative blood flow maps of sham-injected, VEGF- and VEGF+ANG1-treated 
hind limbs attained from dynamic contrast-enhanced computed tomography. Display 
field of view = 5cm.  B. Blood flow decreased in all but two mice over the course of the 
study. Blood flow was not affected by either treatment groups compared to the sham 
controls. n=5 for sham, n=6 for VEGF, n=5 for VEGF+ANG1, by one-way ANOVA. 
Error bars represent SD. 
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Figure 4.4: Ischemia-related reduction in blood volume is circumvented by 
VEGF+ANG1 treatment in mdx/utrn+/- hind limb skeletal muscle. 
A. Representative blood volume maps of sham-injected, VEGF- and VEGF+ANG1-
treated hind limbs attained from dynamic contrast-enhanced computed tomography. 
Display field of view = 5cm. B. Blood volume decreased in all but two mice over the 
course of the study. Blood volume was not significantly different in sham-injected and 
VEGF-treated hind limbs. VEGF+ANG1 treatment resulted in significantly higher fold-
change in blood volume compared to the VEGF and sham group. n=5 for sham, n=6 for 
VEGF, n=5 for VEGF+ANG1, *P < 0.05, by one-way ANOVA. Error bars represent SD. 
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Figure 4.5: VEGF+ANG1 increases vessel maturation following treatment in 
mdx/utrn+/- GM muscle. 
A. Western blot analysis of total alpha smooth muscle actin (αSMA) expression in GM 
tissue homogenates following treatment. B. Immunohistochemical analysis of αSMA-
positive vessels, represented as percent image area. n=6 for all groups **P < 0.01, ***P < 
0.001, by one-way ANOVA. Error bars represent SD. C. Representative 
immunofluorescence images of αSMA expression in sham-injected, VEGF- and 
VEGF+ANG1-treated GM muscles. D. Growth factor-coated beads are visible at the 
injection site. More αSMA-positive vessels are detected at the injection site of 
VEGF+ANG1-treated hind limbs compared to VEGF-treated hind limbs. Scale bar=100 
μm. 
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4.4.4 VEGF and ANG1 reduce leukocyte infiltration and 
inflammation in gastrocnemius muscle of mdx/utrn+/- mice  
To assess the effect of VEGF alone, or in combination with ANG1, on vascular 
permeability, we measured the level of CD45 expression, indicative of leukocyte 
infiltration (Gordon et al. 2013). Expression was assessed via Western blot and IHC 
analyses (Figure 4.6). While muscle treated with VEGF alone (0.35 ±0.03%) did not 
exhibit significantly different levels of CD45 compared to the sham-injected controls 
(0.29 ±0.04%), co-administration of VEGF and ANG1 did significantly reduce leukocyte 
infiltration (0.15 ±0.04%, p= 0.0084). Since CD45 only identifies infiltrating leukocytes 
and not resident macrophages already present in the skeletal muscle, H&E staining was 
employed to qualitatively assess the general degree of inflammation following treatment. 
Both the sham-injected and VEGF-treated muscles were observed to have diffuse clusters 
of inflammatory cells throughout the muscle. In contrast, muscle treated with 
VEGF+ANG1 exhibited little inflammation, with the majority of tissue devoid of 
inflammation.  
4.4.5 VEGF and ANG1 decrease collagen deposition compared to 
VEGF alone in gastrocnemius muscle of mdx/utrn+/- mice  
To assess the effect of VEGF alone or a combination of VEGF and ANG1 on muscle 
fibrosis, we measured collagen deposition using Masson’s Trichrome stain (Figure 4.7). 
There was no significant difference in collagen deposition between either the sham-
injected (9.82 ± 3.1%) or VEGF-treated (12.61 ± 3.1%) hind limb muscles. In contrast, 
hind limb muscle treated with the combination of VEGF and ANG1 exhibited only 
7.6±2.2% collagen deposition, and this difference was determined to be significantly 
lower than the amount of collagen deposition measured in VEGF-treated muscle 
(p=0.0247). 
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Figure 4.6: VEGF+ANG1 decreases leukocyte infiltration following treatment in 
mdx/utrn+/- GM muscle.    
A. Western blot analysis of CD45 expression in GM tissue homogenates following 
treatment. B. Immunohistochemical analysis of CD45, represented as percent image area. 
n=6 for all groups **P < 0.01 by one-way ANOVA. Error bars represent SD. C. 
Representative immunofluorescence images of a-CD45 expression in sham-injected, 
VEGF- and VEGF+ANG1-treated GM muscles D. H&E staining was used to 
qualitatively assess the extent of inflammation following treatment. Inflammatory foci 
are present in all groups, but only small, sparse clusters are present in muscle that 
received the VEGF+ANG1 treatment. Scale bar=100 μm 
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Figure 4.7: VEGF+ANG1 decreases collagen deposition following treatment in 
mdx/utrn+/- GM muscle.    
A. Representative Masson’s Trichrome-stained tissue sections of sham-injected, VEGF- 
and VEGF+ANG1-treated GM muscles. Scale bar=100 μm B. Quantification of collagen 
deposition (blue), represented as percent image area. n=6 for all groups *P < 0.05 by one-
way ANOVA. Error bars represent SD. 
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4.5 Discussion 
Vascular endothelial growth factor (VEGF) and angiopoietin-1 (ANG1) are 
increasingly being considered for their potential role in reducing or attenuating the 
muscle ischemia observed in patients with Duchenne muscular dystrophy (DMD) 
(McClung et al 2015). While prior studies suggest a potential role for these factors in 
enhancing endogenous repair and cell therapy, studies remain to directly investigate the 
effects of either factor on functional perfusion in a non-invasive manner. Therefore, in 
the present study, we utilized the mdx/utrn+/- mouse, a murine DMD model more prone 
to fibrosis than the commonly used mdx mouse, to measure functional perfusion via 
dynamic contrast-enhanced computed tomography (DCE-CT). The short-term effect of 
VEGF alone or in combination with ANG1 was assessed following a low dose, localized 
delivery for 16 days.  Given the high degree of variability between animals with respect 
to baseline perfusion parameters, the ability to monitor vascular-targeted therapy over 
time in the same animal is particularly valuable. DCE-CT is a safe and effective means to 
monitor both disease progression and therapeutic efficacy and shows promise for scaling 
preclinical studies directly to patients (Stewart et al 2006, Sahani et al 2007). Importantly, 
we provide the first evidence that VEGF alone is not sufficient to affect functional 
perfusion parameters in the hind limb skeletal muscle at the dose and duration 
investigated. In comparison, co-administration of VEGF and ANG1 reduced muscle 
ischemia over the course of the treatment period, as evidenced by a less marked reduction 
in blood volume relative to control groups. This finding also highlights the importance of 
investigating perfusion parameters other than blood flow alone, since the physiological 
variability of this measurement can overshadow key observations. Blood flow is subject 
to a number of environmental cues that vastly change flow measurements, such as 
temperature, fasting, exercise, and stress. While blood volume may also be affected by 
these factors, it is a more stable function that has the ability to represent changes in the 
intravascular compartment, or the space that can be perfused during the flow of blood. In 
addition to the functional measurements observed in this study, we further report that 
VEGF+ANG1 significantly reduced muscle inflammation related to either sham-injection 
or VEGF treatment alone, as well as fibrosis, relative to VEGF treatment alone.  
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The findings from this study highlight the importance of considering the stage of 
disease progression in assessing vascular therapy. During the first weeks of life, murine 
models of DMD display classic signs of rapid degeneration and regeneration, 
accompanied by a robust inflammatory response. This phase is accompanied by a 
transient increase in perfusion as assessed by DCE-CT (Ahmad et al 2011).  By nine-ten 
weeks of age, the disease evolves to a more degenerative state and fibrosis begins to 
predominate, coinciding with a progressive decrease in perfusion. Having critically 
identified a window of opportunity to intervene with therapeutics, the present study 
aimed to assess the ability of a combination of VEGF and ANG1 to slow or attenuate 
chronic inflammation, ischemia and fibrosis in DMD mice.  Our data on endogenous 
expression of the two growth factors further points to differences in the vasculature at 
different phases of disease progression. Although we did not measure differences in 
either growth factor in the hind limb (gastrocnemius) muscle, there was a significant 
reduction in both VEGF+ANG1 in the diaphragm. Since the diaphragm develops overt 
fibrosis and muscle degeneration much earlier than hind limb muscles, these differences 
may point to possible differences in expression of VEGF+ANG1 in the hind limb at later 
time points. Overall, having well-defined margins between the different disease states 
could reveal valuable information regarding the effects of VEGF+ANG1 on perfusion, 
vascular permeability, and fibrosis.  
Given that we did not measure any beneficial functional effects from a low dose 
of VEGF under the conditions used here, it would be worth investigating whether 
exogenous VEGF treatment is even necessary or if ANG1 alone may be sufficient to 
affect change, particularly at earlier stages of disease pathogenesis prior to the onset of 
overt fibrosis. Since both growth factors were decreased in the more severely affected 
diaphragm muscle, exogenous administration of these factors at a later disease stage may 
have an even greater impact on ischemia than what we observed here. In addition to its 
role in promoting vascular maturity, previous work by others has shown that ANG1 
promotes satellite cell self-renewal and inhibits apoptosis (Abou-Khalil et al 2013). 
Research in other vascular-related diseases such as cardiac ischemia and sepsis have 
uncovered the deleterious effect that low circulating levels of ANG1 may play in these 
states (Novotny et al 2008, Lee et al 2011). In human microvascular endothelial cells 
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(HMVECs), serum from sepsis patients induced intercellular gap formation, and this 
effect was reversed by supplementation with ANG1 (Parikh et al 2006). 
Prior studies have suggested that VEGF treatment decreases fibrosis (Deasy et al 
2009; Beckman et al 2013), whereas we reported an increase in collagen deposition 18 
days post-treatment compared to VEGF+ANG1 treated hind limbs. This finding is in line 
with our previous work showing that VEGF induces stress fiber formation in fibroblasts 
derived from the GM and diaphragm muscles of mdx/utrn+/- mice. We have also 
demonstrated an increase in expression of alpha-smooth muscle actin mRNA in 
diaphragm fibroblasts following VEGF treatment. Importantly, studies in other fibrotic 
diseases including idiopathic pulmonary fibrosis and scleroderma have shown that VEGF 
exacerbates disease pathology (Maurer et al. 2014 & Hostettler et al. 2014). Still, 
previous work in the DMD field has pointed to an anti-fibrotic role of VEGF. A few 
variables could account for this discrepancy. The use of the mdx/utrn+/- mouse rather 
than the mdx mouse, which our group has validated as a more suitable model due to its 
increased development of fibrosis, may be more responsive to VEGF than its mdx 
counterpart. This hypothesis speaks to the seed and soil theory whereby the mdx/utrn+/- 
tissue may be “primed” to respond to VEGF and develop fibrosis, relative to the mdx 
mouse. Another important consideration that may account for the differences between our 
findings and those of others with respect to fibrosis is the disease stage assessed in the 
current study. A number of studies use either young (5 to 7 week-old) or aged (6 month 
old) mdx mice (Messina et al 2007). It is therefore possible that VEGF plays a reduced 
pro-fibrotic role in both the early phase of the disease when acute inflammation 
predominates and in later phases of the disease when overt fibrosis has occurred in the 
muscle. Lastly, the dose used in this study is much lower than some doses cited in 
previous studies and may account for differential effects on collagen deposition following 
treatment. Regardless, a study in rabbit skeletal muscle has also indicated that long-term 
delivery of VEGF increases collagen deposition. Cumulatively, these findings suggest 
that the effect of VEGF on fibrosis may significantly impede its use as a therapeutic 
factor in DMD. Based on the results presented here, the pro-fibrotic effect of VEGF is 
circumvented when co-administered with ANG1. 
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There is a critical need to detect disease changes such as ischemia in early stages 
so that therapies can be developed before damage, i.e., fibrosis, is extensive and 
irreversible. Advanced non-invasive imaging technologies have immense potential to 
achieve this; we have used dynamic contrast-enhanced computed tomography (DCE-CT) 
and positron emission tomography (PET) to identify transient “spikes” in perfusion and 
18F-fluorodeoxyglucose (18F-FDG) uptake, respectively, in the hind limb muscles of 
preclinical mouse models of DMD (Ahmad et al 2011). Intensity of these spikes 
correlates with disease severity, degree of inflammation, and development of muscle 
fibrosis. Importantly, these studies identified a window of opportunity to intervene with 
therapeutics aimed at slowing/attenuating the inflammatory/ischemic/fibrotic process, as 
demonstrated in the present study. Further use of these technologies to delineate how 
vascular therapies augment either endogenous muscle repair or cell replacement therapy 
represent an innovative and critical approach to the treatment of muscle degenerative 
disorders. 
Future directions will aim to develop methods to better control the delivery of 
angiogenic factors. Although it is well accepted that cell-based delivery systems 
effectively deliver high payloads, there remains concerns regarding their potential pro-
tumorigenic side effects, particularly with regards to VEGF administration (Lee et al). 
Additionally, although we focused on the hind limb muscles in the current study, vascular 
therapy will need to be effective in other muscles involved in disease progression, 
particularly the diaphragm and cardiac muscles. Indeed, fibrosis and degeneration in 
these tissues account for a majority of fatalities in DMD, and therefore any promising 
treatment will need to affect these muscles as well. The fact that the combination 
treatment of VEGF+ANG1 resulted in a significant effect that was detected not only 
histologically but also functionally supports further investigation for the use of these 
factors in long term management of DMD-related ischemia, inflammation, and fibrosis. 
  
108 
 
4.6 References 
Abdel-Salam E, Abdel-Meguid I, Korraa S. Markers of degeneration and regeneration in 
Duchenne muscular dystrophy. Acta Myol. 2009;28(3):94–100. 
Abdel-Salam E, Abdel-Meguid IE, Shatla R, Korraa SS. Stromal cell-derived factors in 
Duchenne muscular dystrophy. Acta Myol. 2010;29(3):398–403. 
Abou-Khalil R, et al. Autocrine and paracrine angiopoietin 1/Tie-2 signaling promotes 
muscle satellite cell self-renewal. Cell Stem Cell. 2009;5:298–309.  
Ahmad N, et al. Use of imaging biomarkers to assess perfusion and glucose metabolism 
in the skeletal muscle of dystrophic mice. BMC Musculoskelet Disord. 2011;12: 127.  
Beckman SA, et al. Beneficial effect of mechanical stimulation on the regenerative 
potential of muscle-derived stem cells is lost by inhibiting vascular endothelial 
growth factor. Arterioscler Thromb Vasc Biol. 2013;33(8):2004-12. 
Brudno Y, Ennett-Shepard AB, Chen RR, Aizenberg M, Mooney DJ. Enhancing 
microvascular formation and vessel maturation through temporal control over 
multiple pro-angiogenic and pro-maturation factors. Biomaterials. 2013;34(36):9201-
9. 
Cenic A, Nabavi DG, Craen RA, Gelb AW, Lee TY. Dynamic CT measurement of 
cerebral blood flow: a validation study. AJNR Am J Neuroradiol. 1999;20(1):63-73. 
Chae JK, et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor 
enhances collateral vascularization. Arterioscler Thromb Vasc Biol. 2000; 
20(12):2573-8. 
Chen F, Tan Z, Dong CY, Chen X, Guo SF. Adeno-associated virus vectors 
simultaneously encoding VEGF and angiopoietin-1 enhances neovascularization in 
ischemic rabbit hind-limbs. Acta Pharmacol Sin. 2007;28(4):493-502. 
109 
 
Daly, C et al. (2004). Angiopoietin-1 modulates endothelial cell function and gene 
expression via the transcription factor FKHR (FOXO1). Genes Dev. 2004;18(9), 
1060–1071.  
Deasy BM, Feduska JM, Payne TR, Li Y, Ambrosio F, Huard J. (2009). Effect of VEGF 
on the Regenerative Capacity of Muscle Stem Cells in Dystrophic Skeletal Muscle. 
Mol Ther. 2009;17(10):1788–1798.  
Fukuhara S, Sako K, Noda K, Nagao K, Miura K, Mochizuki N. Tie2 is tied at the cell-
cell contacts and to extracellular matrix by Angiopoietin-1. Exp Mol Med.  
2009;41(3):133–139.  
Fukuhara S, Sako K, Noda K, Zhang J, Minami M, Mochizuki N. Angiopoietin-1/Tie2 
receptor signaling in vascular quiescence and angiogenesis. Histol Histopathol. 
2010;25(3):387-96. 
Gamble JR, et al. Angiopoietin-1 is an antipermeability and anti-inflammatory agent in 
vitro and targets cell junctions. Circ Res. 2000;87:603–607. 
Gavard J, Patel V, Gutkind JS. Angiopoietin-1 prevents VEGF-induced endothelial 
permeability by sequestering Src through mDia. Dev Cell. 2008;14(1):25-36.  
Gordon BS, Delgado Díaz DC, Kostek MC. Resveratrol decreases inflammation and 
increases utrophin gene expression in the mdx mouse model of Duchenne muscular 
dystrophy. Clin Nutr. 2013;32(1):104-11. 
Grady RM, Teng H, Nichol MC, Cunningham JC, Wilkinson RS, Sanes JR. Skeletal and 
cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne 
muscular dystrophy. Cell. 1997; 90(4):729-38 
Gregorevic P, et al. Systemic delivery of genes to striated muscles using adeno-associated 
viral vectors. Nat Med. 2004;10(8):828-34.  
110 
 
Gutpell KM, Hrinivich WT, Hoffman LM. Skeletal Muscle Fibrosis in the mdx/utrn+/- 
Mouse Validates Its Suitability as a Murine Model of Duchenne Muscular Dystrophy. 
PLoS ONE. 2015;10(1): e0117306. 
Hostettler KE, et al. Anti-fibrotic effects of nintedanib in lung fibroblasts derived from 
patients with idiopathic pulmonary fibrosis. Respir Res. 2014;15:157-66 
Iivanainen E, et al. Angiopoietin-regulated recruitment of vascular smooth muscle cells 
by endothelial-derived heparin binding EGF-like growth factor. FASEB J. 
2003;17(12):1609-21. 
Karvinen H, et al. Long-term VEGF-A expression promotes aberrant angiogenesis and 
fibrosis in skeletal muscle. Gene Ther. 2011;18(12):1166-72.  
Kobayashi H, DeBusk LM, Babichev YO, Dumont DJ, Lin PC. Hepatocyte growth factor 
mediates angiopoietin-induced smooth muscle cell recruitment. Blood. 
2006;108(4):1260–1266. 
Lee RJ, Springer ML, Blanco-Bose WE, Shaw R, Ursell PC, Blau HM. VEGF gene 
delivery to myocardium: deleterious effects of unregulated expression. Circulation. 
2002;102(8):898-901. 
Lee SW, et al. Angiopoietin-1 protects heart against ischemia/reperfusion injury through 
VE-cadherin dephosphorylation and myocardiac integrin-β1/ERK/caspase-9 
phosphorylation cascade. Mol Med. 2011;17(9-10):1095-106.  
Loufrani L, et al. Absence of dystrophin in mice reduces NO-dependent vascular function 
and vascular density: total recovery after a treatment with the aminoglycoside 
gentamicin. Arterioscler Thromb Vasc Biol. 2004;24(4):671-6. 
Maurer B, et al. Vascular endothelial growth factor aggravates fibrosis and vasculopathy 
in experimental models of systemic sclerosis. Ann Rheum Dis. 2014;73(10):1880-7 
111 
 
Messina S, et al. VEGF overexpression via adeno-associated virus gene transfer promotes 
skeletal muscle regeneration and enhances muscle function in mdx mice. Faseb J. 
2007;21(13):3737-46.  
McClung JM, et al. Muscle cell derived angiopoietin-1 contributes to both myogenesis 
and angiogenesis in the ischemic environment. Front Physiol. 2015;6:161 doi: 
10.3389/fphys.2015.00161 
Mofarrahi M, et al. Angiopoietin-1 enhances skeletal muscle regeneration in mice. Am J 
Physiol Regul Integr Comp Physiol. 2015;308(7):R576-89.  
Nico B et al. HIF activation and VEGF overexpression are coupled with ZO-1 up-
phosphorylation in the brain of dystrophic mdx mouse. Brain Pathol. 2007;17(4):399-
406. 
Novotny NM, et al. Angiopoietin-1 in the treatment of ischemia and sepsis. Shock. 
2009;31(4):335-41. 
Nguyen F, Guigand L, Goubault-Leroux I, Wyers M, Cherel Y. Microvessel density in 
muscles of dogs with golden retriever muscular dystrophy. Neuromuscul Disord. 
2005;15(2):154-63. 
Palladino M, et al. Angiogenic impairment of the vascular endothelium: A novel 
mechanism and potential therapeutic target in muscular dystrophy. Arterioscler 
Thromb Vasc Biol. 2013;33(12):2867-76. 
Papapetropoulos A, et al. Angiopoietin-1 inhibits endothelial cell apoptosis via the 
Akt/survivin pathway. J Biol Chem. 2000;31;275(13):9102-5. 
Parikh SM, et al. Excess Circulating Angiopoietin-2 May Contribute to Pulmonary 
Vascular Leak in Sepsis in Humans. PLoS Med. 2006;3(3):e46. 
Sahani DV, Holalkere NS, Mueller PR and Zhu AX. Advanced hepatocellular carcinoma: 
CT perfusion of liver and tumor tissue-initial experience. Radiology. 
2007;243(3):736-43. 
112 
 
Shimizu-Motohashi Y, Asakura A. Angiogenesis as a novel therapeutic strategy for 
Duchenne muscular dystrophy through decreased ischemia and increased satellite 
cells. Front Physiol. 2014;5:50. doi: 10.3389/fphys.2014.00050. 
Shyu KG, Chang H, Isner JM. Synergistic effect of angiopoietin-1 and vascular 
endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model 
with acute hindlimb ischemia. Life Sci. 2003;73(5):563-79. 
Stewart E E, Chen X, Hadway J and Lee T Y 2006 Correlation between hepatic tumor 
blood flow and glucose utilization in a rabbit liver tumor model. Radiology. 2006 
239(3):740-50.  
Taylor SC, Berkelman T, Yadav G, Hammond M. A Defined Methodology for Reliable 
Quantification of Western Blot Data. Mol Biotechnol. 2013;55(3): 217–226. 
Yamauchi A, et al. Pre-administration of angiopoietin-1 followed by VEGF induces 
functional and mature vascular formation in a rabbit ischemic model. J Gene Med 
2003;5(11):994-1004. 
Zacchigna S, et al. In vivo imaging shows abnormal function of vascular endothelial 
growth factor-induced vasculature. Hum Gene Ther. 2007;18(6):515-24. 
Zhou L, et al. Haploinsufficiency of utrophin gene worsens skeletal muscle inflammation 
and fibrosis in mdx mice. J Neurol Sci. 2008;264(1–2):106–11. 
 
113 
 
Chapter 5  
 
Discussion  
114 
 
5 General Discussion 
 
5.1 Chapter Summary 
The research described in this thesis includes studies that advance current knowledge of 
vascular-targeted therapy for the treatment of Duchenne muscular dystrophy. 
Importantly, very little has been reported on whether vascular-targeted therapy may 
confer functional benefits to the muscle and how angiogenic growth factors may affect 
fibrosis. This research is novel in that it investigates the effect of VEGF, alone or in 
combination with ANG1, in the mdx/utrn+/- mouse, a clinically relevant murine model 
that mimics the manifestation of DMD in patients. We focused our studies on the phase 
of disease progression when acute and rapid inflammation transitions into fibrotic 
deposition and muscle degeneration, which is around 8-10 weeks of age in the 
mdx/utrn+/- mouse. Given this tightly controlled timeline, we have elucidated some key 
findings that have not been previously reported (Table 5.1). An important consideration is 
that findings presented in this thesis include work conducted in a murine model of 
Duchenne muscular dystrophy and therefore conclusions made here may not fully 
translate to human DMD patients. Additionally, there are specific limitations to each 
study that are discussed in the following section. Overall, this chapter will summarize the 
important conclusions drawn from each study, discuss key limitations to the research, and 
propose future investigative directions that will be crucial prior to moving vascular 
therapy into patients.  
  
115 
 
 
Table 5.1: Summary of findings from studies described in chapters 2, 3, and 4.  
DM: Diaphragm muscle; GM: gastrocnemius muscle; dko: double knockout (mdx/utrn-/-
); : increased; : decreased 
 
 
  
Chapter 2 
Comparison of three murine 
models of DMD 
Chapter 3 
Effect of VEGF on DMD 
fibroblasts in vitro 
Chapter 4 
Effect of VEGF & ANG1 in vivo 
Young & aged mdx/utrn+/- mice 
exhibit more GM fibrosis than mdx 
mice 
VEGF does not affect collagen or 
Ctgf/ccn2 gene expression in DM or 
GM fibroblasts 
Endogenous [VEGF] and [ANG1]: 
mdx/utrn+/- < wild-type 
Fibrosis: 
GM << diaphragm (for all 3 models) 
VEGF ! αSMA gene expression 
DM fibroblasts 
VEGF+ANG1 " hind limb ischemia 
Extent of fibrosis is not different 
among hind limb muscle groups 
VEGF ! fibronectin in DM and GM 
fibroblasts 
VEGF+ANG1, but not VEGF alone, 
! vessel maturation 
Disease severity:  
mdx < mdx/utrn+/- << dko 
VEGF ! differentiation of GM and 
DM fibroblasts into myofibroblasts 
VEGF+ANG1 " leukocyte 
infiltration, inflammation 
mdx/utrn+/- is the most suitable 
model for assessing longitudinal 
effects of vascular therapy  
DM fibroblasts are more responsive 
to pro-fibrotic cues than GM 
fibroblasts 
VEGF+ANG1 " fibrosis 
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5.2 Conclusions by chapter 
5.2.1 Chapter 2- Selection of the mdx/utrn+/- mouse for DMD 
research 
The aim of Chapter 2 was to determine which murine model would be best suited to our 
research goals for investigating vascular-targeted therapy for DMD. Disease progression 
in mdx, mdx/utrn+/-, and dko mice was compared to that of healthy wild type controls. 
We demonstrate that, by as early as seven to eight weeks of age, the heterozygous 
mdx/utrn+/- mouse exhibits more collagen deposition (indicative of fibrosis) than age-
matched mdx littermates. Another important finding from this study was that collagen 
deposition in the mdx mouse was not determined to be significantly higher than that 
observed in healthy hind limb muscle. Other groups have shown that mdx skeletal muscle 
is fibrotic compared to healthy muscle, so the discrepancy between the literature and our 
findings may lie in that fact that fibrosis was compared on a spectrum along with 
mdx/utrn+/- and dko muscle tissue and the effect size in our study is larger than that 
comparing only mdx and wild-type.  
Since our research focuses heavily on the effects on fibrosis of angiogenic growth factors, 
particularly VEGF, this study allowed us to make intelligent decisions regarding the age 
and model best suited to assess these effects. As a result, we incorporated 9-10 week-old 
male mdx/utrn+/- mice in all subsequent studies as these mice are in the “post’ fibrotic 
phase where significant collagen deposition has occured. This is a key consideration for 
all DMD research. There are a number of studies that utilize young mdx mice and 
subsequently report decreases in fibrosis (Deasy et al., 2009; Beckman et al., 2013). 
Using an animal that is pre-fibrotic and drawing such conclusions may lead to 
misinterpretation of the results and could explain some differences in our results 
compared to those found in the literature. 
Although use of the mdx/utrn+/- mouse allows us to offer conclusions regarding the 
effect of angiogenic growth factors on fibrosis, it is clear from the findings of our study 
that the dko mouse remains, by far, the most severely affected and perhaps most accurate 
model of DMD. Since mdx/utrn+/- mice, like their mdx counterparts, may live up to 1-2 
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years of age in a laboratory setting, the disease severity is not considered fatal as it is in 
the dko mouse. As such, future studies assessing functional efficacy of treatment should 
also seek to assess effects in the dko mouse prior to scaling studies to large animals or, 
especially, to patients.  
Overall, the findings from this study have a profound impact in the field of DMD 
research, but some limitations did exist. Disease severity in mdx, mdx/utrn+/- and dko 
gastrocnemius (GM) and diaphragm muscles was compared to healthy wild type 
gastrocnemius and diaphragm muscles of C57BL/6 mice. Although C57BL/6 mice are 
the most commonly used inbred strain, C57BL/10 mice should have been used in this 
study since the mdx mouse was generated on this background and not the Bl6 
background. A few studies have investigated whether behavioural and immunological 
differences exist between these two strains (Deacon et al. 2007, McClive et al. 1994, 
Slingsby 1995). While the differences appear to be minor, the results from these studies 
highlight the need to properly select control strains. Although we would not anticipate 
this discrepancy to affect conclusions drawn from the study, for the purpose of scientific 
soundness, C57BL/10s were included for wild type controls in all subsequent studies.  
Although collagen deposition occurs earlier in this model compared to the mdx mouse, 
whether or not the difference between the two is sufficient to affect function is not 
known. We used the term “collagen deposition” synonymously with “fibrosis,” but there 
may in fact be a certain degree of collagen deposition that does not exert a negative 
impact on muscle function. Therefore, our finding that increased collagen deposition by 
7-8 weeks of age classifies the mdx/utrn+/- mouse as “more fibrotic” is an important 
assumption and should be kept in mind when referring to both models in terms of 
fibrogenesis.  
Our use of C57Bl6 mice as the healthy control model and use of a limited definition of 
fibrosis still revealed importance differences between the mdx and mdx/utrn+/- murine 
models. The limitations discussed here, if addressed, would only bolster the key findings 
observed in Chapter 2. Since there is increasing focus on the importance of fibrosis in 
DMD, many groups are looking for superior murine models to the mdx mouse, and the 
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work in this study is the first to show that phenotypic differences in collagen deposition 
arise at a young age between mdx and mdx/utrn+/- mice. One of the most important 
initial steps in designing a study is selection of a suitable animal model in which to 
challenge hypotheses. This study rigorously tested the murine models available to us and 
allowed us to definitively decide to incorporate the mdx/utrn+/- mouse in all subsequent 
studies described in this thesis. This decision thus allows us to tie a number of findings 
that contrast previously reported findings to the use of a model that is not commonly 
cited in the literature, opening the door for a new understanding of the effects of vascular 
therapy in DMD. 
 
5.2.2 Chapter 3- Role of VEGF in eliciting a fibrotic response 
The aim of the studies described in Chapter 3 was to investigate whether exogenous 
levels of VEGF may exacerbate the fibrotic response in fibroblasts derived from the 
mdx/utrn+/- mouse. In other fibrotic diseases, particularly idiopathic pulmonary fibrosis, 
elevated VEGF levels correlate with more rapid disease progression. Whether this 
relationship is causative or correlated is not fully understood. Studies in rodents indicate 
that blocking VEGF signaling can reduce fibrosis in mice and administering VEGF 
exogenously can exacerbate fibrosis in rats (Hamada et al. 2005; Farkas et al. 2009). 
Given these observations in other pathologies, we sought to determine whether VEGF 
might play a role in increasing fibrosis in DMD fibroblasts. Although we did not observe 
robust induction of a fibrotic response following VEGF treatment, as we did following 
TGFβ treatment, there were multiple findings that may point to a possible role of the 
growth factor in exacerbating fibrosis. Collagen and Ccn2/ctgf gene expression were 
unaffected by VEGF treatment. Interestingly, we did not measure an increase in 
fibronectin  (Fn1) gene expression following treatment with either VEGF or TGFβ. 
When we assessed protein expression, FN levels increased following VEGF but not 
TGFβ treatment. This is a particularly interesting finding since TGFβ is well known to 
induce FN production in fibroblasts derived from lung and other fibrotic tissues, and we 
did not observe such a response here (Torr et al. 2015; Serini et al. 1998). VEGF binding 
domains have been identified on FN, and it has been shown that VEGF binding to FN 
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increases the biological activity of VEGF by promoting a physical interaction between 
the type 2 VEGF receptor (VEGFR-2) and its integrin α5β1 receptor (Wijelath et al. 
2002). Given the role of this interaction, it is plausible that VEGF treatment resulted in 
increased protein levels, but not as part of a fibrotic response. VEGF expression has been 
shown to increase following FN administration, but not the other way around, as we 
observed in this study. This is a finding that warrants further exploration. 
One of the most intriguing findings from this study is that VEGF increased gene 
expression of alpha smooth muscle actin (Acta2) in diaphragm fibroblasts. Gene 
expression increased to a level similar to that following TGFβ treatment. Although VEGF 
led to a 1.4-fold increase in Acta2 expression in GM fibroblasts, this change was not 
considered significant given the high variability in this data set. As such, it should not be 
fully accepted that VEGF does not induce αSMA gene expression in fibroblasts derived 
from the GM muscle. In both GM and diaphragm fibroblasts, we observed formation of 
αSMA-positive stress fibers, a hallmark feature of myofibroblasts, following VEGF 
treatment. Myofibroblasts are a major cellular contributor to fibrotic tissue and 
differentiation of fibroblasts into this more contractile phenotype is suggestive of 
induction of the fibrotic response. These findings point to a potential role of VEGF in 
exacerbating fibrosis in DMD, which is a finding that contradicts previous studies 
showing a decrease in fibrosis following VEGF treatment in mdx mice. 
There are some areas for improvement that could be addressed in future studies. Previous 
research in the past decade has highlighted the importance of an appropriate substrate for 
culturing and investigating fibroblasts in vitro (Hinz et al. 2015).  Mimicking 
physiological substrate stiffness relevant to the tissue of interest is key in reproducing 
cellular responses that accurately reflect the in vivo scenario. Although the differences in 
our findings between diaphragm and GM-derived fibroblasts indicate their fibrotic 
phenotypes were maintained in culture, some changes might have resulted due to our 
culturing on a collagen skim coat rather than a three-dimensional matrix. In vivo, tissues 
range from very soft, such as bone marrow, to very hard, such as bone. Muscle tissue is 
mid-range, but moderately stiff compared to many other tissues. The culture conditions 
should attempt to mimic the stiffness of skeletal muscle ECM since others have shown 
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that matrix stiffness determines the biological activity of TGFβ available to cells. Thus, if 
our culture conditions were “too stiff,” there may have been an abundance of TGFβ 
available to produce a basal fibrotic response in all treatment groups. This explanation 
may account for the relatively low fold increase in gene expression observed in the TGFβ 
treatment group. Although this is a possibility in our study, we do not believe it played a 
major role in affecting our data since our immunocytochemistry results reveal little 
differentiation in the untreated control fibroblasts compared to either TGFβ- or VEGF-
treated cells. If our culture conditions were severely affecting TGFβ levels, we would 
have expected to see a high degree of differentiation in the fibroblasts, indicated by 
αSMA-positive stress fibers.  
Although resident fibroblasts are the most studied cell type involved in fibrogenesis, 
recent work by others has revealed a possible role for others cells in the process as well. 
Pericytes, which are located around the endothelium and are surrounded by basal lamina, 
have been shown to differentiate into myofibroblasts and contribute to ECM production 
(Schrimpf et al. 2011).  The exact role of pericytes in healthy and diseased skeletal 
muscle has not been well defined, and this is in part due to the fact that different sub-
populations of pericytes may have different roles in skeletal muscle repair, angiogenesis, 
innervation, adipogenesis, and fibrosis (Dellavalle et al. 2007, Birbrair et al. 2013a,b,c). 
Thus, without proper isolation of specific subtypes, information gleaned from pericyte 
studies could under- or overestimate their role in fibrosis. For example, only a specific 
subpopulation of Nestin-NG2+ pericytes has been shown to have myogenic properties 
capable of regenerating muscle. Another sub-population of nestin+NG2+ pericytes, 
termed type 1 pericytes, participates in fibrogenesis in aged skeletal muscle. These type 1 
pericytes, when stimulated with TGFβ, produce collagen and are positive for fibroblast-
specific protein 1. It should be noted, though, this fibrogenic capacity of type 1 pericytes 
is more pronounced in aged mice, and it has not be fully determined whether these cells 
play a role in non-age related fibrotic disease such as DMD (Birbrair et al. 2013d). 
Fibro/adipogenic progenitor cells (FAPs) have also been identified recently as a cell type 
contributing to fibrogenesis (Joe et al. 2010, Uezumi et al. 2010, 2011, Judson et al. 2013, 
Contreras et al. 2016). Like pericytes, these cells can undergo myogenesis and repair 
injured muscle or during the aging process. These integrin-α7−Sca1+PDGFR-α+ cells 
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have been identified as a major source of extracellular matrix production in repair 
mechanisms of healthy skeletal muscle. In normal repair processes, these FAPS 
proliferate upon injury, heal the damaged muscle, and then become quickly quiescent 
until once again needed. In the mdx mouse, this normal process appears to be affected 
and FAP numbers do not sufficiently reduce during the repair process and therefore 
contribute to the fibrogenic pool of cells (Lemos et al. 2015).  
It is well accepted that myofibroblasts are the major source of fibrosis in DMD and other 
diseases (Klingler et al., 2012). The knowledge gap that currently exists lies in not fully 
understanding the origin of these myofibroblasts. Work by others has demonstrated a role 
for pericytes and FAPs in the fibrogenic response. The study described in chapter 3  
assessed the effect of vascular therapy on resident fibroblasts. Whether VEGF elicits a 
fibrotic response in these other cell types is not currently known and we cannot 
extrapolate our conclusions to apply to FAPS and pericytes. Thus, given the potency of 
these cells in promoting fibrogenesis, future studies should address the possibility of off-
target effects of VEGF on these cell populations as well. 
Though these other cell populations remain to be explored, VEGF elicited some 
components of a fibrotic response in resident DMD fibroblasts, which is a novel finding 
that has not been previously reported. Additionally, we show that fibroblasts derived 
from environments that differ in disease severity (i.e. diaphragm and GM muscles), are 
phenotypically distinct and respond differently to pro-fibrotic cues. Taken together, these 
results reveal unexplored territory for future work and could drastically alter our 
understanding of the interplay between fibrosis and angiogenesis in DMD.   
 
5.2.3 Chapter 4- Effect of VEGF and ANG1 on Functional 
Perfusion 
The aim of chapter 4 was to determine what effect, if any, pro-angiogenic factors exert on 
functional perfusion in vivo in the mdx/utrn+/- mouse. Specifically, we sought to 
determine whether VEGF alone, when delivered locally, was sufficient to affect 
functional perfusion or if another factor is required. In this study, we tested VEGF alone 
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or in combination with angiopoietin-1 (ANG1). Dynamic contrast-enhanced computed 
tomography (DCE-CT) was employed to assess the efficacy of vascular-targeted therapy 
in dystrophic murine skeletal muscle in affecting blood flow and blood volume. DCE-CT 
is a novel way to examine muscle perfusion because it can assess global blood flow 
throughout the hind limb, a benefit not afforded by other modalities such as laser Doppler 
imaging. Although perfusion decreased over the duration of the study, consistent with 
progression of ischemia, the degree to which blood volume decreased was less marked in 
mice that received VEGF+ANG1 in combination. We did not measure a significant effect 
using VEGF alone when compared to the sham-injected group. Assessment of vessel 
maturation, indicated by αSMA-positive vessels, validated the imaging findings.  In 
addition to vessel maturation, the combination VEGF+ANG1 treatment resulted in 
reduced collagen deposition and leukocyte infiltration compared to either the sham or 
VEGF group, suggesting a potential anti-fibrotic and anti-inflammatory role of 
VEGF+ANG1 in DMD.  
Because the previous study, described in chapter 3, suggested VEGF may enhance the 
fibrotic response in DMD, we investigated the effect of VEGF with and without ANG1 
on fibrosis in vivo. Our statistical analysis determined that collagen deposition was not 
significantly different between sham-injected and VEGF-treated hind limbs, but the 3% 
difference in collagen deposition should not be overlooked, as this may be sufficient to 
have a biological effect in muscle function. Lastly, the only measure of fibrosis we 
assessed in this study was collagen deposition via Masson’s Trichrome stain. Even 
though VEGF did not exacerbate collagen deposition compared to the sham control, 
further analysis of other fibrotic markers such as FN and CCN2/CTGF could reveal 
different findings.  
Since we showed that vessel maturation was increased following VEGF+ANG1 
treatment and leukocyte infiltration was decreased, we concluded this reduction in 
inflammatory cells at the site of muscle injury could play a role in reducing fibrosis. 
Since inflammatory cells are the major source of TGFβ (which then acts on fibroblasts to 
induce extracellular matrix production) reducing the number of these cells in muscle 
tissue may be an effective way to reduce chronic inflammation that lays the foundation 
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for the eventual fibrosis. Although we quantitatively assessed infiltration of CD45-
positive leukocytes, we only performed a qualitative analysis of total inflammation using 
the hematoxylin and eosin stain. Infiltrating leukocytes are not the only cellular player 
involved in skeletal muscle inflammation, so analysis of resident macrophages may 
reveal an even further role of ANG1 in reducing inflammation. 
The delivery system used to administer growth factor treatment to mdx/utrn+/- hind limb 
muscle in chapter 4 represents one of the most important limitations to this study. 
Alginate beads were coated with VEGF or a combination of VEGF and ANG1. Beads 
prepared for sham injection were soaked in PBS. Although we performed proof-of-
principle studies to confirm presence of growth factor up to a minimum of 14 days post-
implant (Appendix C), we were unable to calibrate the actual dose of growth factor 
delivered. Insulin syringes were used for injections and some beads always remained in 
the hub of the needle following implant. Further, we did not determine the variability in 
coating efficiency for either growth factor. Given these considerations, we cannot 
ascertain that a consistent dose of either VEGF or ANG1 was administered each time. 
Further, although the alginate beads are relatively small, ranging in size from 50 to 
100um, the bolus of beads (approximately 100 per injection) remained at the injection 
site for as little as 4 weeks post-implant. Given this observation, the beads themselves 
may have induced a minor chronic inflammatory response, which may have contributed 
to overall disease progression. Although we attempted to deliver just a localized dose, our 
analyses reveal that the GFs likely exerted systemic effects, as evidenced by a lack of 
difference in perfusion between control and treated contralateral hind limbs.  Localized 
drug delivery can often be beneficial, particularly in cases where potent or toxic drugs are 
administered, but systemic delivery may be the ideal outcome here given the systemic 
effects of disease progression. Overall, the limitations involved with this bead delivery 
system highlight the need to deliver a targeted dose of growth factor, ideally 
systemically, to account for these sources of variability in this study.  
Use of DCE-CT has drastically improved patient care for other ischemic diseases such as 
stroke (d’Esterre et al. 2012). Whether it is the optimal non-invasive imaging modality 
for assessing vascular targeted therapy deserves further consideration.  The reduction in 
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perfusion observed in this study correlates to the time when fibrosis begins to contribute 
to a significant portion of the skeletal muscle. Thus, an assumption made here is the 
ischemia observed functionally is, at least in part, due to the progression of fibrosis. Since 
fibrotic and non-fibrotic muscle tissue does not differ sufficiently in density, these tissues 
cannot be well delineated on an anatomical CT scan. It would therefore be valuable to use 
another imaging modality capable of measuring fibrotic tissue to validate this decline in 
perfusion and corresponding increase in fibrosis. Since MRI can distinguish tissues 
composed of differing water content, fibrotic tissue appears as a lower signal area than 
surrounding skeletal muscle (McIntosh et al., 1998; Chen et al. 2006). Combining MRI 
perfusion with anatomical imaging of fibrotic areas could strengthen the findings we 
attained from CT perfusion. Other groups have used MRI to assess vasomodulation in 
humans following exercise with and without taking vasoregulating compounds. 
Assessing vasodilation and blood oxygenation could be another useful tool in further 
clarifying assumptions made in our study (Bulte et al. 2006; Towse et al. 2005). 
While taking into account these limitations, this study described a novel way to assess the 
functional effects of vascular therapy for DMD using a non-invasive, clinically relevant 
approach. In addition, in contrast to other reports, we do not observe an anti-fibrotic 
effect of VEGF following treatment, a finding that could be partially explained by our 
unique use of the mdx/utrn+/- murine model. Building on the findings from Chapter 3, 
we demonstrate potential deleterious effects of VEGF alone as a treatment for DMD and 
show these effects can be avoided when combined with ANG1.   
 
5.3 Future directions 
The conclusions drawn from this thesis examining vascular therapy in the mdx/utrn+/- 
mouse have resulted in a number of questions that remain to be answered. Some of our 
unanticipated findings have generated new avenues to explore and may eventually 
expedite the use of vascular therapy in DMD patients. There are also a number of 
findings from our in vivo work that may be extended to other fibrotic and vascular-related 
diseases. 
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Given the increasing attention that fibrosis is receiving for its devastating effects in 
DMD, future research that explores this aspect of the disease could reveal new insights to 
this process. Our in vitro work assessing the effect of VEGF on the fibrogenic response in 
resident fibroblasts pointed to altered fibrotic phenotypes based on the muscle from 
which these cells were derived. Since we demonstrate that diaphragm fibroblasts are 
more responsive to TGFβ and VEGF while GM fibroblasts appear to be more resistant to 
these cues, we hypothesize altered signaling occurring in these different populations. 
Future work in our lab will focus on performing microarray gene analysis to determine if 
there is a novel gene or combination of genes that is/are up- or down-regulated in fibrotic 
cells. Work in Dupuytren’s disease, a fibrotic disease of the palmar fascia, reveals 
differential gene expression in fibroblasts isolated from the lesion versus fibroblasts 
parallel to the lesion (Satish et al. 2008). These findings suggest that similar profile 
differences could exist in diaphragm versus GM fibroblasts to reveal potentially novel 
molecular targets for future treatments.   
 One of the most encouraging findings attained from this research was that VEGF+ANG1 
treatment prevents overt ischemia, as was observed with VEGF treatment alone. Future 
studies should aim to determine whether VEGF is even necessary to achieve the desired 
effects from vascular therapy or if ANG1 treatment alone is sufficient. Given that VEGF 
produces leaky vasculature and it is implicated in hemangioma formation when 
administered at a sufficiently high dose, avoiding exogenous use of this growth factor 
might be ideal in DMD (Lee et al. 2000). Use of ANG1 in other disease models such as 
acute lung injury and sepsis suggest that protecting against vascular leakage is a powerful 
approach for attenuating undesired downstream consequences (Huang et al. 2008; Fang et 
al. 2015). Future studies in our lab should also seek to use cartilage oligomeric matrix 
protein (COMP)-ANG1, a soluble ANG1 derivative that has more potent effects on the 
Tie2 receptor than does ANG1 (Cho et al. 2004, 2005, Ryu et al. 2015).  
Although work in other fields point to the possibility of using ANG1 alone as a treatment, 
further work is required to assess whether the effect of VEGF on endogenous repair and 
cell therapy is ultimately a justified use of the growth factor as a treatment. Since prior 
studies have shown that VEGF enhances efficacy of cell therapy by optimizing paracrine 
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effects, VEGF may still play an important therapeutic role that is independent of its effect 
on perfusion (Beckman et al. 2013). Having now identified a disease time point whereby 
intervention might be optimal, future studies in our lab will investigate whether vascular-
targeted therapy will enhance survival of satellite cell transplants. Since it is well 
accepted that transplanted cells exert their effects by way of paracrine signaling, 
increasing their survival post-transplant may be an effective way of enhancing their 
function. Future studies in our lab will use other non-invasive imaging modalities to 
target satellite cells post-implant (Appendices G-I). Satellite cells expressing luciferase 
and/or a mutant herpes simplex virus type 1 sr39 thymidine kinase can be non-invasively 
targeted using bioluminescence or positron emission tomography imaging, respectively 
(Ray et al., 2007. Thus, we can directly assess the effect of VEGF on cell transplant 
survival in longitudinal manner that circumvents the need for repeated ex vivo analysis.   
A promising new avenue for vascular therapy is development of a targeted delivery 
system. Targeted drug delivery is a rapidly emerging in the field of cancer research for 
delivering chemotherapy drugs and radioligands for tumour treatment and imaging, 
respectively (Khaw et al., 2014). Use of a targeted drug delivery system could have a 
number of benefits for vascular therapy in DMD. A targeted system would circumvent 
the use of viral delivery as well as allow for systemic delivery to all damaged muscle, 
especially ones that are difficult to reach via intramuscular injection such as the 
diaphragm. This ability to target the diaphragm may be the most important factor since 
disease progression in the respiratory muscles is the major contributing factor to DMD 
mortality (Khirani et al., 2014). In all three murine models of DMD discussed in this 
thesis, fibrosis and muscle degeneration in the diaphragm far exceeds that observed in the 
hind limb muscles. Thus, regardless of the animal model used, any study that reports 
efficacy in the diaphragm represents more potential than efficacy reported elsewhere in 
the body. Systemic delivery would also allow for administration of low doses with little 
off target effects, addressing the issues related to hemangioma formation following 
VEGF treatment.  In order to develop a targeted drug delivery system, a marker specific 
to damaged muscle will need to be identified. Markers that would be up regulated in the 
inflammatory response, such as CCR2 and E-selection, or markers up regulated in the 
fibrotic response, such as CCN2/CTGF or ADAM12, are attractive candidates 
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(Mojumder et al. 2014, Farini et al. 2007). A key consideration here is targeting a 
biomarker without affecting function, if function is still desired. On the other hand, 
neutralizing the activity of some of these markers with the use of an antibody might have 
synergistic effects that add to the benefits of vascular therapy. 
Overall, the research described in this thesis links two-dimensional histological effects of 
vascular therapy to non-invasive, global changes following treatment. Future work should 
answer questions relating to vascular therapy that we did not investigate within the body 
of this work. Three-dimensional histopathology reconstruction and intravital video 
microscopy may describe parameters of angiogenic therapy not answered by DCE-CT. 
Such parameters include vessel enlargement, tortuosity, blood oxygenation, and degree of 
branching/bifurcation following treatment (Xu et al., 2015; Frontini et al., 2011; Novielli 
& Jackson, 2014). Combining our findings with these techniques may have profound 
impacts on the way we utilize vascular-targeted therapy in the context of DMD. 
Despite tremendous advances in care for patients living with DMD, the disease remains 
invariably fatal. Vascular-targeted therapy is just one therapeutic approach currently 
under investigation. While the findings described in this thesis support the use of pro-
angiogenic growth factors for DMD, it is the prevalent opinion in the field that any 
eventual cure will involve a multifaceted approach. Thus, our long-term goal is to work 
in concert with groups investigating ways to reintroduce dystrophin to DMD patients, a 
combinatorial approach that may truly extend life expectancy and, importantly, improve 
quality of life.  
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Appendix A: Colour thresholding to analyze collagen content in histological sections 
stained with Masson’s Trichrome. 
 
Quantifying collagen deposition in Masson’s Trichrome stained tissue sections. 5um 
sections of gastrocnemius tissue were stained with Masson’s Trichrome (A,B) on 
separate days and imaged on a Zeiss Microscope using different exposure windows, 
producing different hues of blue (collagen) and orange (muscle).  Images were 
transformed into Lab colour space allowing the isolation of the colour and lightness 
components of each pixel. A k-means clustering algorithm was then applied to the colour 
components of each individual image to partition the pixels into groups of relatively ‘red’ 
or ‘blue’ colour values (C,D).  
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Appendix B: Fibroblasts isolated from dystrophic mdx/utrn+/- mice. 
 
Primary fibroblasts isolated from mdx/utrn+/- muscle. Fibroblasts migrate away from 
tissue explants (shown above: diaphragm fibroblasts). Immunocytochemistry confirms 
presence of fibroblasts by assessing vimentin and CCN2 expression. Scale bar=50μm.  
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Appendix C: ELISA analysis demonstrates that localized delivery of vascular 
endothelial growth factor (VEGF165) results in slow release of the growth factor for 
up to two weeks post-injection. 
 
VEGF164 levels following intramuscular implantation of VEGF164-coated beads. 
Alginate beads were coated with 0.5ug of recombinant human VEGF165 and injected into 
the lateral head of the gastrocnemius muscle of mdx mice. At 3, 7, and 14 days post-
injection, mice were sacrificed and tissue was collected for ELISA analysis (n=2 per time 
point). Tissue was collected from four different regions to indicate how far VEGF 
treatment diffused (tissue directly surrounding and including the injection site [black], 
tissue less than 5mm from the injection site [dark grey], tissue more than 1cm from the 
injection site [medium grey], and tissue from the contralateral limb [light grey]). VEGF 
was still measured 14 days post-implant. Note: No cross-reactivity with mouse VEGF164 
was detected using this assay. 
  
Distance from 
injection site 
Very distal 
Directly at site 
Proximal 
Distal 
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Appendix D: Results from initial perfusion study using 5-7 week-old mdx mice  
 
Blood flow and blood volume perfusion maps acquired from DCE-CT scans at 
baseline and two weeks following treatment with pro-angiogenic growth factors. 
Mdx mice were injected with either PBS and VEGF-coated beads (A,C,E,G) or VEGF 
and VEGF+ANG1-coated beads (B,D,F,H) . Mice were scanned at baseline (A,B,E,F) 
and two weeks post-implant (C,D,G,H). Blood flow (A,B,C,D,I) and blood volume 
(E,F,G,H,J) were measured using CT Perfusion 5 software (n=5, p<0.05). 
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Appendix E: Dynamic contrast-enhanced CT scans acquire data that can be used to 
attain functional perfusion maps. 
 
An anatomical and functional map acquired from DCE-CT scans. An axial 
anatomical scan (A) yields cross-sectional images. Bony landmarks such as the tail, 
fibula and tibia are easily identified. A black void is visible after injection of Affi-Gel 
Blue Gel beads (either soaked in PBS or coated with growth factor). Following a bolus of 
iodinated contrast agent, a series of one-second scans are taken to acquire functional data. 
CT Perfusion 5 software is used to generate perfusion maps (B).     
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Appendix F: Quantifying fluorescence images to include αSMA+ blood vessels and 
exclude αSMA+ myofibroblasts 
 
An anti-αSMA primary antibody marks both mature vasculature and 
myofibroblasts in dystrophic muscle. To accurately quantify mature blood vessels 
(green arrows) on histological sections, extreme care must be taken to exclude αSMA+ 
myofibroblasts (pink brackets). Implementation of a semi-automatic grey scale 
thresholding algorithm detects presence of vessels only (pink signal in segmented image).    
Raw immunofluorescence image  
Green arrows 
identify vessels 
Pink brackets 
identify 
myofibroblasts 
Segmented image 
141 
 
 
Appendix G: Molecular Imaging to Target Transplanted Muscle Progenitor Cells4 
Introduction 
Duchenne muscular dystrophy (DMD) is a severe genetic neuromuscular disorder that 
affects 1 in 3,500 boys, and is characterized by progressive muscle degeneration (Emery 
2002; Blake et al. 2002). In patients, the ability of resident muscle satellite cells (SCs) to 
regenerate damaged myofibers becomes increasingly inefficient4. Therefore, 
transplantation of muscle progenitor cells (MPCs)/myoblasts from healthy subjects is a 
promising therapeutic approach to DMD. A major limitation to the use of stem cell 
therapy, however, is a lack of reliable imaging technologies for long-term monitoring of 
implanted cells, and for evaluating its effectiveness. Here, we describe a non-invasive, 
real-time approach to evaluate the success of myoblast transplantation. This method takes 
advantage of a unified fusion reporter gene composed of genes (firefly luciferase [fluc], 
monomeric red fluorescent protein [mrfp] and sr39 thymidine kinase [sr39tk]) whose 
expression can be imaged with different imaging modalities (Ray et al. 2004, 2007). A 
variety of imaging modalities, including positron emission tomography (PET), single-
photon emission computed tomography (SPECT), magnetic resonance imaging (MRI), 
optical imaging, and high frequency 3D-ultrasound are now available, each with unique 
advantages and limitations (Massoud & Gambhir 2003). Bioluminescence imaging (BLI) 
studies, for example, have the advantage of being relatively low cost and high-
throughput. It is for this reason that, in this study, we make use of the firefly luciferase 
(fluc) reporter gene sequence contained within the fusion gene and bioluminescence 
imaging (BLI) for the short-term localization of viable C2C12 myoblasts following 
implantation into a mouse model of DMD (Sicinski 1989; Mattson 2001; Anderson et al. 
                                                 
4
 This appendix includes content reproduced with permission from 
Gutpell K, McGirr R, Hoffman L (2013). Molecular Imaging to Target Transplanted Muscle Progenitor 
Cells. J Vis Exp (73), e50119, doi:10.3791/50119. 
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1988). Importantly, BLI provides us with a means to examine the kinetics of labeled 
MPCs post-implantation, and will be useful to track cells repeatedly over time and 
following migration. Our reporter gene approach further allows us to merge multiple 
imaging modalities in a single living subject; given the tomographic nature, fine spatial 
resolution and ability to scale up to larger animals and humans (Massoud & Gambhir 
2003), PET will form the basis of future work that we suggest may facilitate rapid 
translation of methods developed in cells to preclinical models and to clinical 
applications. 
 
Keywords: Molecular Biology, Issue 73, Medicine, Biophysics, Biomedical Engineering, 
Cellular Biology, Anatomy, Physiology, Genetics, Surgery, Diseases, Musculoskeletal 
Diseases, Analytical, Diagnostic and Therapeutic Techniques and Equipment, 
Therapeutics, Bioluminescence imaging (BLI), Reporter Gene Expression, Non-invasive 
Targeting, Muscle Progenitor Cells, Myoblasts, transplantation, cell implantation, MRI, 
PET, SPECT, BLI, imaging, clinical techniques, animal model 
Protocol 
Maintenance and Propagation of C2C12 Myoblasts 
1. Plate C2C12 myoblasts in a 75 cm2 flask and maintain cells in high glucose 
Dulbecco's Modified Eagle's Serum (HG-DMEM) supplemented with fetal bovine 
serum (FBS) to a final concentration of 10%. Do not allow cells to become confluent 
at any time, as this will deplete the myoblast population. Medium should be changed 
every other day. Note: always warm medium to 37 °C in a water bath prior to use. 
2. When myoblasts become approximately 80% confluent, passage cells to a new flask. 
Aspirate culture medium. Wash cells with 4-5 ml Hanks Balanced Salt Solution 
(HBSS) to remove all traces of culture medium, which contains trypsin-inhibiting 
serum. Briefly rinse the cell layer with 2-3 ml 0.25% (w/v) trypsin-EDTA solution to 
dissociate the adherent myoblasts from the flask. Aspirate trypsin and place flask in 
incubator at 37 °C for 5 min. 
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3. During this incubation, prepare a new flask with 9 ml of HG-DMEM/10% FBS 
medium. After trypsinization, add 10 ml of complete medium to cells and pipette 4-5 
times to ensure collection of all cells in the medium. Add 1 ml of cell suspension to 
the new flask and incubate in 5% CO2 at 37 °C. 
C2C12 Cell Transfection 
1. Once cells have reached 50% confluency, transfect according to manufacturer's 
instructions from Invitrogen. Briefly, combine 90 μl Lipofectamine 2000 reagent with 
4.5 ml OPTI-MEM medium. In another tube, combine 36 μg CMV-trifusion reporter 
gene DNA with 4.5 ml OPTI-MEM. Flick each tube to combine and wait 5 min. 
Combine contents of both tubes, mix gently and incubate at room temperature for 
exactly thirty minutes. Note: A second flask should also be set up for untransfected 
cells that only receive Lipofectamine and OPTI-MEM to serve as a negative control. 
2. Remove medium from C2C12 cells and add 15.5 ml of fresh HG-DMEM/10%FBS 
medium. Add transfection medium to bring total volume to 20 ml. 
3. Allow cells to transfect overnight for at least 20 hr at 37 °C. 
4. Next day, aspirate transfection medium and add 10 ml HG-DMEM/10%FBS. 
5. View cells under an inverted fluorescent microscope. Capture both bright field and red 
fluorescence images (using a TRITC filter cube; mrfp ex/em: 584/607 nm). Count the 
number of RFP-expressing cells viewed under fluorescence divided by total number of 
cells viewed under bright field for multiple fields of view to generate transfection 
efficiency. 
Assessment of Cell Survivability/MTT Assay 
1. One day prior to transfection, plate 1x105 C2C12 cells into each well in a 24-well 
plate. Cells should be plated in 500 μl volumes in HG-DMEM/10%FBS . 
2. Next day, transfect myoblasts overnight as previously described. Follow 
manufacturer's suggestions for transfection reagent volumes for a 24-well plate. 
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Incubate a set of wells with Lipofectamine only (no DNA) as a control. View cells 
under fluorescence to ensure that proper transfection has occurred. 
3. Remove transfection medium and incubate myoblasts with 5 mg/ml thiazolyl blue 
tetrazolium bromide (MTT) in HG-DMEM/10% FBS. Add D-luciferin to eight of the 
transfected wells, and incubate at 37 °C for four hours. 
4. Remove medium from wells. Solubilize blue formazan crystals by adding 180 μl 
isopropanol to each well. Shake at 37 °C for 15 min. 
5. Avoiding any precipitate, pipette solution into a 96-well plate and read absorbance at 
575 nm. 
Preparation of Myoblasts for Transplant 
1. Remove medium, wash myoblasts with HBSS, and trypsinize cells as outlined in 1.1. 
2. Re-suspend cells in 4 ml of complete medium. 
3. Using a hemocytometer, count cells to generate volumes containing 106 myoblasts. 
Pipette volume into sterile 1.5 ml microtubes. With a transfection efficiency of ~10%, 
these values indicate that 100,000 luciferase-expressing cells are detectable on the GE 
ExploreOptix scanner after transplant. 
4. Attain a final injection volume of 15 μl, containing 106 C2C12 cells. If necessary, 
centrifuge microtubes at 2,000 rpm for one minute. Carefully aspirate supernatant with 
a pipette. Re-suspend cells in 15 μl of HG-DMEM lacking FBS. 
Cell Implantation 
1. Anesthetize mouse with 2% isoflurane/2%O2. Pluck hair from the dorsal hind limb 
area. Maintain anesthesia at 1.5%isoflurane/2%O2. 
2. Ensure C2C12 myoblasts are well suspended. With the mouse in a prone position, 
extend the hind limb and use an insulin syringe to inject cells directly into the lateral 
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head of the gastrocnemius muscle at a 30 ° angle. Inject transfected myoblasts into the 
right hind limb and untransfected myoblasts into the contralateral (left) hind limb. 
3. Perform a baseline bioluminescence scan: Quickly transfer mouse to stage in the 
optical scanner, laying the mouse in a prone position. Hook up the anesthetic line. To 
ensure the mouse remains anesthetized, a second person should be present to hook up 
the anesthetic line while the other places the animal in the scanner. 
4. Gently extend the hind limb so the area of injection is visible. Tape hind limbs in place 
with a gentle adhesive such as medical tape. 
5. Close the chamber and ensure that no light can access the interior of the scanner, as 
this will increase the background signal detected. The scanner should be set to 
parameters included in your manufacturer's instructions for bioluminescence imaging. 
Specifically, ensure "no laser" is selected. 
6. Draw a region of interest (ROI) around the plucked area and start scan. 
Injection of Fluc Substrate, D-luciferin, into Mdx Mouse 
1. While the mouse is anesthetised intraperitoneally inject 150 mg/kg of firefly luciferase 
substrate, D-luciferin (from a 40 mg/ml stock solution, made up according to 
manufacturer's instructions). 
2. Recover mouse and allow a 15 min uptake period before preparing mouse for the next 
scan. 
BLI to Target Luc-expressing MPCs Following Implant into Mouse Models of DMD 
1. After the uptake period, anesthetise mouse again, as described in 5.1. 
2. Transfer the mouse back to the optical scanner and perform another bioluminescence 
scan in the same manner as the background scan. 
3. Although a 20 min uptake period should provide maximal signal intensity, a 
subsequent scan may be performed. 
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4. Upon completion of image acquisition, sacrifice the mouse according to guidelines set 
by your Institutional Animal Ethics Committee and the Canadian Council on Animal 
Care (CCAC). Isolate hind limb muscle and place immediately in 10% formalin to fix 
for paraffin embedment. Perform immunohistochemistry staining for luciferase to 
confirm intramuscular injection of myoblasts. 
Representative Results 
Upon 50-60% confluency, C2C12 myoblasts were transiently transfected with the above-
mentioned fusion reporter gene construct composed of firefly luciferase [fluc], 
monomeric red fluorescent protein [mrfp] and sr39 thymidine kinase [sr39tk](Figure 1A). 
Transfection efficiency was calculated via fluorescence microscopy (Figures 1B,C), 
making use of the mrfp sequence in our reporter construct. Cell survivability was not 
affected by labeling with the BLI substrate, D-luciferin (Figure 1D). Following 
transfection, approximately 100,000 mrfp-expressing myoblasts were implanted 
intramuscularly into the gastrocnemius muscle of mdx mice (determined previously); 
100,000 untransfected cells were similarly implanted into the contralateral hind limb as a 
control. Immediately following cell implantation, mice were injected intraperitoneally 
(IP) with 150 mg/kg D-luciferin. Following an uptake period of ~20 min, mice were 
imaged on a small animal optical scanner (GE ExplorOptix black box that is equipped for 
live animal bioluminescence and fluorescence). As previously demonstrated, both in vitro 
and post-implantation (manuscript submitted) uptake of D-luciferin were specific to fluc-
expressing myoblasts, with no detectable bioluminescence in untransfected cells (Figure 
2). Immunohistochemistry confirmed intramuscular transplantation of myoblasts. 
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Figure 1. Schematic of CMV-trifusion reporter construct (A); brightfield/fluorescence 
images of C2C12 myoblasts transfected with the trifusion reporter plasmid (B,C); MTT 
assay to assess C2C12 cell survivability following labeling with BLI substrate, D-
luciferin (D). 
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Figure A2. Bioluminescence imaging (BLI). BLI targets luciferase-expressing cells 
following transplant (A). A region of interest is drawn to enclose the plucked hind limb 
area where myoblasts are injected. Bioluminescence is not detected during a background 
scan. At 23 min after injection of D-luciferin, a clear signal is detected from the right 
hind limb where luciferase-expressing myoblasts are injected. No bioluminescence is 
detected in the contralateral hind limb injected with untransfected myoblasts. IHC using a 
firefly luciferase antibody confirms intramuscular implantation of transfected C2C12 
cells (B). DAPI was used as a counterstain. Scale bar= 50um. 
  
A
B
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Discussion 
In this study, we have described a fast and reliable molecular imaging, reporter gene 
approach to non-invasively target myoblasts/MPCs following transplantation. While this 
study demonstrates the short-term localization of transplanted MPCs via bioluminescence 
imaging (BLI), the manner in which cells are targeted can, in fact, be easily applied to a 
longitudinal assessment of cell engraftment, through the implantation of cells that stably 
express the reporter gene. To this end, our group has generated transgenic mouse lines 
that harbour the unified reporter gene. Only cells expressing the reporter gene oxidize D-
luciferin to produce photons for visualization using BLI. Since oxidation of D-luciferin is 
dependent on gene expression, this is a powerful technology with which to non-
invasively image viable transplanted cells. Muscle tissue harvested from these transgenic 
mice and satellite cells (SCs) isolated via FACS can indeed be targeted following 
implantation into mdx mice. Additionally, we can track their differentiation status 
through the use of a muscle-specific promoter, further heightening the usefulness and 
importance of molecular imaging technologies, such as presented herein, to the field of 
DMD research. In addition to its rapidity and low-cost, BLI is non-toxic, making it an 
attractive choice for frequent imaging of small animals. This feature, as well as its high 
specificity, will be invaluable in refining myoblast replacement therapies in pre-clinical 
disease models of Duchenne muscular dystrophy before advancing to clinically 
applicable studies involving technologies such as PET. 
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Appendix H: C2C12 myoblasts expressing the trifusion reporter under control of 
the myogenin promoter can be targeted ex vivo following injection   
Immunohistochemistry confirms intramuscular implantation of myogenin-FMT-
expressing C2C12 myoblasts. Differentiated C2C12 myoblasts transiently transfected 
with myogenin-FMT DNA express mRFP (A). Bright field and fluorescence images 
reveal an expression level of less than 1% (A, B) scale bar=50µm. One million C2C12 
cells (10,000 luciferase-expressing) are transplanted into the hind limb muscle of an mdx 
mouse. Immunohistochemistry confirms intramuscular implant (C-E). 
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Appendix I: Fluorescence activated cell sorting of satellite cells from transgenic 
mice expressing a trifusion imaging reporter driven by the muscle-specific promoter 
myogenin 
 
 
Satellite cells FACS-isolated from a transgenic myogenin-FMT mouse. Satellite cells 
are sorted based on positive staining of alpha-7 integrin, negative staining of the lineage 
markers CD31, CD45, CD11b and Ly6A/E, and a forward-scatter high profile (A). After 
7 days in culture, satellite cells differentiate into myogenin-expressing myocytes that 
express the mRFP reporter (B,C). Immunocytochemistry confirms differentiation along 
the myogenic pathway, as indicated by the expression of MyoD and myogenin. MyoD, an 
early indicator of myoblast activation, is not expressed in more differentiated cells where 
myogenin is expressed (scale bar=50µm). 
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